EX-10.1





 Exhibit 10.1 

EXECUTION VERSION 
 CONFIDENTIAL
– Subject to FRE 408 
 THIS RESTRUCTURING SUPPORT AGREEMENT DOES NOT CONSTITUTE (NOR SHALL IT BE CONSTRUED AS) AN OFFER WITH RESPECT TO ANY
SECURITIES OR A SOLICITATION OF ACCEPTANCES OR REJECTIONS AS TO ANY PLAN OF REORGANIZATION. ANY SUCH OFFER OR SOLICITATION WILL COMPLY WITH ALL APPLICABLE PROVISIONS OF SECURITIES, BANKRUPTCY, AND/OR OTHER APPLICABLE LAWS. 

 
  

 
 RESTRUCTURING SUPPORT AGREEMENT

 AMONG 

ENDOLOGIX, INC. 
 AND

 THE SUPPORTING LENDERS IDENTIFIED HEREIN 

DATED AS OF JULY 5, 2020 
  

 
  












 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
		
	ARTICLE I	  	 	 
		
	DEFINITIONS	  	 	 
			
	 Section 1.1
	 	 Defined Terms
	  	 	6	 
	 Section 1.2
	 	 Terms Defined Elsewhere in this Agreement
	  	 	15	 
		
	ARTICLE II	  	 	 
		
	DEFINITIVE DOCUMENTS	  	 	 
			
	 Section 2.1
	 	 Incorporation of Exhibits and Schedules
	  	 	17	 
	 Section 2.2
	 	 Definitive Documents
	  	 	17	 
		
	ARTICLE III	  	 	 
		
	COMMITMENTS OF THE SUPPORTING LENDERS	  	 	 
			
	 Section 3.1
	 	 Support of Restructuring
	  	 	17	 
	 Section 3.2
	 	 Rights of Supporting Lenders Unaffected
	  	 	19	 
	 Section 3.3
	 	 Transfer of Claims
	  	 	20	 
		
	ARTICLE IV	  	 	 
		
	COMMITMENTS OF THE COMPANY	  	 	 
			
	 Section 4.1
	 	 Commitments of the Company
	  	 	20	 
	 Section 4.2
	 	 Rights of the Debtors Unaffected
	  	 	23	 
		
	ARTICLE V	  	 	 
		
	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	  	 	 
			
	 Section 5.1
	 	 Qualification, Organization, Subsidiaries, etc.
	  	 	24	 
	 Section 5.2
	 	 Capitalization
	  	 	24	 
	 Section 5.3
	 	 Corporate Authority
	  	 	25	 
	 Section 5.4
	 	 Consents and Approvals
	  	 	26	 
	 Section 5.5
	 	 No Violations
	  	 	26	 
	 Section 5.6
	 	 SEC Filings; Financial Statements
	  	 	27	 
	 Section 5.7
	 	 No Undisclosed Liabilities
	  	 	28	 
	 Section 5.8
	 	 Absence of Certain Changes
	  	 	28	 
	 Section 5.9
	 	 Brokers or Finders
	  	 	29	 
	 Section 5.10
	 	 Litigation
	  	 	29	 
	 Section 5.11
	 	 Intellectual Property
	  	 	30	 


  
 i 














							
	 Section 5.12
	 	 Data Privacy and Cybersecurity; IT Assets
	  	 	31	 
	 Section 5.13
	 	 Real Property Leases
	  	 	32	 
	 Section 5.14
	 	 Material Contracts
	  	 	32	 
	 Section 5.15
	 	 Compliance with Laws; Anticorruption; Permits; Trade Compliance
	  	 	35	 
	 Section 5.16
	 	 Employee Benefit Matters
	  	 	37	 
	 Section 5.17
	 	 Labor Matters
	  	 	38	 
	 Section 5.18
	 	 Environmental Matters
	  	 	39	 
	 Section 5.19
	 	 FDA and Related Regulatory Matters
	  	 	39	 
	 Section 5.20
	 	 Taxes
	  	 	42	 
	 Section 5.21
	 	 Insurance
	  	 	43	 
	 Section 5.22
	 	 No Other Representations; No Reliance
	  	 	43	 
		
	ARTICLE VI	  	 	 
		
	REPRESENTATIONS AND WARRANTIES OF THE SUPPORTING LENDERS	  	 	 
			
	 Section 6.1
	 	 Qualification; Organization
	  	 	44	 
	 Section 6.2
	 	 Corporate Authority
	  	 	44	 
	 Section 6.3
	 	 Consents and Approvals
	  	 	45	 
	 Section 6.4
	 	 No Violations
	  	 	45	 
	 Section 6.5
	 	 Brokers
	  	 	45	 
	 Section 6.6
	 	 Ownership of Claims
	  	 	46	 
	 Section 6.7
	 	 No Other Representations; No Reliance
	  	 	46	 
		
	ARTICLE VII	  	 	 
		
	COVENANTS	  	 	 
			
	 Section 7.1
	 	 Interim Operations
	  	 	47	 
	 Section 7.2
	 	 Access and Information
	  	 	50	 
	 Section 7.3
	 	 Approvals and Consents; Cooperation; Notification
	  	 	50	 
	 Section 7.4
	 	 Employee Communications
	  	 	51	 
	 Section 7.5
	 	 Alternative Transaction Procedures
	  	 	51	 
	 Section 7.6
	 	 Insurance
	  	 	52	 
		
	ARTICLE VIII	  	 	 
		
	CONDITIONS PRECEDENT	  	 	 
			
	 Section 8.1
	 	 Conditions to Obligation of the Company and the Supporting Lenders
	  	 	53	 
	 Section 8.2
	 	 Conditions to Obligation of the Company
	  	 	53	 
	 Section 8.3
	 	 Conditions to Obligation of the Supporting Lenders
	  	 	54	 
	 Section 8.4
	 	 Frustration of Conditions
	  	 	55	 


  
 ii 














							
	ARTICLE IX	  	 	 
		
	TERMINATION	  	 	 
			
	 Section 9.1
	 	 Termination
	  	 	55	 
	 Section 9.2
	 	 Termination Upon Effective Date or Outside Date
	  	 	58	 
	 Section 9.3
	 	 Effect of Termination
	  	 	59	 
		
	ARTICLE X	  	 	 
		
	GENERAL PROVISIONS	  	 	 
			
	 Section 10.1
	 	 Agreement Effective Time
	  	 	60	 
	 Section 10.2
	 	 No Solicitation
	  	 	60	 
	 Section 10.3
	 	 Purpose of Agreement
	  	 	60	 
	 Section 10.4
	 	 Admissibility of this Agreement
	  	 	61	 
	 Section 10.5
	 	 Several, Not Joint Obligations
	  	 	61	 
	 Section 10.6
	 	 Survival
	  	 	61	 
	 Section 10.7
	 	 Public Announcements
	  	 	61	 
	 Section 10.8
	 	 Notices
	  	 	61	 
	 Section 10.9
	 	 Descriptive Headings; Interpretative Provisions
	  	 	62	 
	 Section 10.10
	 	 Representation by Counsel; No Strict Construction
	  	 	63	 
	 Section 10.11
	 	 Entire Agreement
	  	 	63	 
	 Section 10.12
	 	 Governing Law and Venue; Waiver of Jury Trial
	  	 	63	 
	 Section 10.13
	 	 Transaction Expenses
	  	 	64	 
	 Section 10.14
	 	 Amendments and Waivers
	  	 	64	 
	 Section 10.15
	 	 Parties, Succession and Assignment
	  	 	65	 
	 Section 10.16
	 	 No Waiver of Participation and Reservation of Right
	  	 	65	 
	 Section 10.17
	 	 No Third-Party Beneficiaries
	  	 	66	 
	 Section 10.18
	 	 Counterparts; Effectiveness
	  	 	66	 
	 Section 10.19
	 	 Severability
	  	 	66	 
	 Section 10.20
	 	 Specific Performance
	  	 	66	 
	 Section 10.21
	 	 Conflicts
	  	 	66	 

 Schedule 1 Company Subsidiaries 

Exhibit A Restructuring Term Sheet 
 Exhibit B Interim
DIP Order 
 Exhibit C Form of Transfer Joinder 
 Exhibit D
Milestones 

  
 iii 













 RESTRUCTURING SUPPORT AGREEMENT 

This RESTRUCTURING SUPPORT AGREEMENT (as amended, modified or supplemented from time to time in accordance with the terms hereof, and
including all exhibits, annexes, schedules and attachments hereto, this “Agreement”), dated as of July 5, 2020, is entered into by and among Endologix, Inc., a Delaware corporation (“Endologix” or the
“Company”), on behalf of itself and its Subsidiaries listed on Schedule 1 hereto (each, a “Company Subsidiary” and collectively, the “Company Subsidiaries,” and, together with Endologix, each
a “Debtor,” and collectively, the “Debtors”), Deerfield Partners, L.P. (“DPLP”), Deerfield Private Design Fund III, L.P. (“PDIII”) and Deerfield Private Design Fund IV, L.P.
(“PDIV” or “Term Loan Agent”, and together with DPLP and PDIII, the “Supporting Lenders”), the lenders pursuant to that certain Amended and Restated Facility Agreement, dated as of August 9,
2018 (as amended, supplemented, or otherwise modified from time to time in accordance with the terms thereof, the “Prepetition Facility Agreement”), by and among the Term Loan Agent, as agent, and the Supporting Lenders, as lenders,
the lenders pursuant to that certain Credit Agreement, dated as of August 9, 2018 (as amended, supplemented, or otherwise modified from time to time in accordance with the terms thereof, the “Prepetition Credit Agreement”), by
and among Deerfield ELGX Revolver, LLC, as agent (in such capacity, the “ABL Agent”, and together with the Term Loan Agent the “Prepetition Agents”), and the Supporting Lenders, as lenders (the “Prepetition
Lenders”). The Company and the Supporting Lenders are each referred to herein as a “Party” and collectively, the “Parties.” Capitalized terms used herein but not otherwise defined have the meanings ascribed
to them in the Restructuring Term Sheet. 
 RECITALS 

WHEREAS, the Debtors are engaged in the business of, directly or indirectly, researching, developing, manufacturing, marketing and selling
medical devices for the treatment of aortic disorders (including abdominal aortic aneurysms (“AAA”)) and other products that are as of the date of this Agreement being researched, developed, tested (including through clinical
trials), commercialized, manufactured, stored, sold, licensed, or distributed by or on behalf of any of the Debtors, including (i) the AFX® Endovascular AAA System, (ii) the Ovation® Abdominal Stent Graft System (including the Ovation Alto® Abdominal Stent Graft System) and (iii) the Nellix® Endovascular Aneurysm Sealing System (such business, the “Business”; and such products, including (i)-(v) and any other medical devices,
materials, methods, processes, materials, products or therapies, that are distributed by the Company, including those that have been acquired, or have been or are under development, manufacture, distribution or commercialization, by or on behalf of
any of the Debtors (including any Affiliate thereof), taken together, the “Products”); 
 WHEREAS, the Company and the ABL
Agent entered into that certain Forbearance Agreement, dated May 26, 2020 (as amended from time to time, the “Term Loan Forbearance Agreement”), under which the ABL Agent agreed to forbear from exercising certain
default-related rights and remedies against the Company with respect to certain specified defaults under the Prepetition Credit Agreement; 

  
 4 













 WHEREAS, the Prepetition Agents hold first priority (subject to certain Permitted Liens (as
defined in the Prepetition Credit Agreement and Prepetition Facility Agreement)) liens on all Collateral, Patent Collateral and Trademark Collateral, as applicable (as defined in the Prepetition Security Agreements), which includes all of the assets
of the Debtors, including all Company Intellectual Property, except for Excluded Property and Excluded Accounts (as defined in the Prepetition Security Agreements); 

WHEREAS, as of the date and time of this Agreement, the Company has not commenced a case under chapter 11 of Title 11 of the United
States Code (the “Bankruptcy Code”); 
 WHEREAS, the Parties have negotiated a restructuring of the Company (the
“Restructuring”) which shall be implemented in accordance with a pre-negotiated chapter 11 plan of reorganization, a copy of which has been provided to the Prepetition Agents (the “Plan”) that implements a
reorganization and recapitalization of the Company pursuant to chapter 11 cases (the “Chapter 11 Cases”) commenced under the Bankruptcy Code in the United States Bankruptcy Court for the Northern District of
Texas (the “Bankruptcy Court”) which will be filed on the Petition Date (as defined below), and which will be subject to the Debtors’ evaluation of Alternative Transactions in accordance with the terms hereof; 

WHEREAS, subject to the Company’s evaluation of Alternative Transactions as set forth herein, the Restructuring contemplated by this
Agreement shall be implemented upon the terms and conditions set forth in the term sheet attached hereto as Exhibit A (together with all exhibits, schedules, and attachments thereto and as amended, supplemented, or
otherwise modified from time to time in accordance with the terms hereof, the “Restructuring Term Sheet”); 
 WHEREAS,
subject to Bankruptcy Court approval, the Debtors have obtained the agreement of the Prepetition Agents for (a) the DIP Facility (as defined below) on the terms and conditions set forth in a debtor-in-possession credit agreement, whose form and substance shall be acceptable to the DIP Agent and the Company and (b) the consensual use of “cash collateral” in each case pursuant to the
terms and conditions of the proposed DIP order attached hereto as Exhibit B (the “Interim DIP Order”) and a proposed final order to be on terms substantially identical to the terms set forth in the Interim
DIP Order with such changes necessary to convert the Interim DIP Order into a final order (the “Final DIP Order” and together with the Interim DIP Order the “DIP Orders” and each a “DIP Order”) to
be entered by the Bankruptcy Court in form and substance mutually acceptable to the Company and the DIP Agent; 
 WHEREAS, in order to
effectuate the Restructuring, the Debtors intend to file petitions commencing (the date of commencement being the “Petition Date”) the Chapter 11 Cases under chapter 11 of the Bankruptcy Code; 

WHEREAS, this Agreement is the product of arm’s-length, good-faith negotiations among the Parties
and is not intended to be and shall not be deemed to be a solicitation of acceptances of any chapter 11 plan; and 
 WHEREAS, the
Parties have agreed to support the Restructuring subject to and in accordance with the terms of this Agreement and to use commercially reasonable efforts to 

  
 5 













 
complete the negotiation of the terms of the documents and completion of the actions specified to effect the Restructuring in accordance with the Restructuring Term Sheet. 

NOW, THEREFORE, in consideration of the promises and mutual covenants and agreements herein contained and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties covenant and agree as follows: 
 ARTICLE I

 DEFINITIONS 

Section 1.1 Defined Terms. As used in this Agreement, the following terms have the following meanings: 

“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled by, or
is under common control with, such Person, and the term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise. 

“Agreement” has the meaning set forth in the Preamble and shall include the Exhibits, Annexes and Schedules annexed hereto or
referred to herein. 
 “Alternative Transaction” means (i) any alternative refinancing, recapitalization, share
exchange, rights offering, equity investment or other transaction or any purchase, sale, or other disposition of all or a material portion of a Debtor’s business or assets, except for the sale of assets in the ordinary course of business, in
each case, other than pursuant to the Restructuring, (ii) any issuance, sale, or other disposition of any equity interest (including securities or instruments directly or indirectly convertible or exchangeable into equity but excluding any
intercompany transactions necessary or desirable in connection with the Restructuring) in a Debtor (by such Debtor) in each case other than the Restructuring, (iii) any merger, acquisition, consolidation, or other business combination
transaction involving a Debtor (excluding any intercompany transactions necessary or contemplated in connection with the Restructuring) or (iv) any other reorganization, restructuring or other transaction the purpose or effect of which is to
restructure a significant portion of the Debtor’s business or assets or result in a significant reduction of the Debtors’ outstanding indebtedness. 

“Antitrust Laws” means any applicable supranational, national, federal, state, county or local antitrust, competition or
trade regulation Laws that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening competition through merger or acquisition, including the HSR Act, the
Sherman Act, the Clayton Act and the Federal Trade Commission Act, in each case, as amended, and other similar antitrust, competition or trade regulation Laws of any jurisdiction other than the United States. 

“Approved KEIP” means that certain Key Employee Incentive Plan as consented to by the Supporting Lenders prior to the
Petition Date. 

  
 6 













 “Approved KERP” means that certain Key Employee Retention Plan as consented
to by the Supporting Lenders prior to the Petition Date. 
 “Board” means the Board of Directors of Endologix. During the
term of this Agreement, the Board shall at all times include one (1) independent director designated by the Agent (as defined in the Term Loan Forbearance Agreement) in accordance with the terms of the Term Loan Forbearance Agreement. 

“Books and Records” means all documents of, or otherwise in the possession, custody or control of, or used by, the Debtors in
connection with, or relating to, the Business or the operations of the Debtors, including all books and records (financial, laboratory and otherwise), files, instruments, papers, microfilms, photographs, letters, budgets, forecasts, ledgers,
journals, title policies, lists of past, present and/or prospective customers, supplier lists, regulatory filings, billing records, and patient support and market research programs and related databases, documents relating to the filing,
prosecution, maintenance, enforcement or defense of Intellectual Property, technical documentation (design specifications, functional requirements, operating instructions, manufacturing procedures, methods, and records, validation protocols and
records, supplier qualification and purchasing information, logic manuals, flow charts, etc.), user documentation (installation guides, user manuals, training materials, release notes, working papers, etc.), data (including safety data, clinical
trial data, patient data), reports (including environmental reports and assessments), plans, mailing lists, price lists, marketing information and procedures, advertising and promotional materials, equipment records, warranty information, architects
agreements, construction contracts, drawings, plans and specifications, records of operations, standard forms of documents, and related books, records and workpapers, manuals of operations or business procedures and other similar procedures
(including all discs, tapes and other media-storage data containing such information), all non-conforming material reports and assessments, complaint files and adverse event files in the safety and quality
databases of the Debtors or their Affiliates, in each case, whether or not in electronic form. 
 “Business Day” means any
day other than Saturday, Sunday and any day that is a legal holiday or a day on which banking institutions in New York, New York are authorized by Law or other governmental action to close. 

“Business Permits” means all Permits that are required for the operation of the Business, in each case, as conducted or owned
and used by the Debtors on the date of this Agreement. 
 “Cause of Action” means any action, suit, claim, complaint,
litigation, investigation, proceeding, arbitration or other similar dispute by or before any Governmental Entity. 

“Claim” means any “claim” (as defined in section 101(5) of the Bankruptcy Code) against the Debtors. 

“Code” means the Internal Revenue Code of 1986, as amended. 

“Company Intellectual Property” means all Intellectual Property owned or purported to be owned by the Company or any of its
Subsidiaries, including all Company Registered Intellectual Property (other than Company Registered Intellectual Property identified on Section 5.11(a)(ii) of the Company Disclosure Letter), and all of the Company’s and each of its


  
 7 













 
Subsidiaries’ rights therein, and, in the case of Trademarks, all goodwill associated with or symbolized thereby. 

“Company IT Assets” means the IT Assets owned, used or held for use by any of the Company or any of its Subsidiaries. 

“Company Specified Representations” means the representations and warranties contained in the first sentence of
Section 5.1, Section 5.3 and Section 5.9. 

“Confirmation Order” has the meaning set forth in the Restructuring Term Sheet. 

“Contract” means any agreement, commitment, promise, undertaking, contract, subcontract, settlement agreement, lease,
sublease, instrument, permit, concession, franchise, binding understanding, note, option, bond, mortgage, indenture, trust document, loan or credit agreement, license, sublicense, insurance policy or other legally binding commitment or instrument,
whether written or oral. 
 “Copyrights” means all copyrights and applications for copyright. 

“Debtor Plan” means any benefit or compensation plan, program, policy, practice, agreement, contract, arrangement or other
obligation, whether or not in writing and whether or not funded, in each case, which is sponsored or maintained by, or required to be contributed to, or with respect to which any potential liability is borne by, any of the Debtors or any of their
Subsidiaries. Debtor Plans include, but are not limited to, “employee benefit plans” within the meaning of Section 3(3) of ERISA, whether or not subject to ERISA, employment, consulting, retirement, severance, separation, termination
or change in control agreements, relocation, repatriation, expatriation, termination pay, performance awards, bonuses, incentives, equity-based awards, phantom equity, supplemental retirement, deferred compensation, profit sharing, insurance,
medical, welfare, fringe or other benefits, but excluding any such plans established pursuant to statute. 
 “Deerfield”
means Deerfield Management Company, L.P. and its Affiliates. 
 “Definitive Documents” has the meaning set forth in the
Restructuring Term Sheet. 
 “DIP Agent” has the meaning set forth in the Restructuring Term Sheet. 

“DIP Facility” has the meaning set forth in the Restructuring Term Sheet. 

“Disclosure Statement” has the meaning set forth in the Restructuring Term Sheet. 

“Disclosure Statement Order” means the order to be entered by the Bankruptcy Court approving the Disclosure Statement and
Solicitation Materials as containing, among other things, “adequate information” as required by section 1125 of the Bankruptcy Code. 

“Effective Date” means the date that the Plan becomes effective. 

  
 8 













 “Encumbrance” means any lien, pledge, hypothecation, mortgage, deed of
trust, security interest, encumbrance, covenant, charge, claim, lease, sublease, option, right of first refusal, easement, servitude, restrictive covenant, encroachment, right of use or possession, right of way, encroachment, occupancy right,
preemptive right, community property interest or restriction of any nature, whether arising prior to or subsequent to the commencement of the Chapter 11 Cases, and whether imposed by Law, Contract or otherwise. 

“Entity” has the meaning set forth in Section 101(15) of the Bankruptcy Code. 

“Environmental Laws” means all Laws relating to the protection of the environment. 

“Equity Interests” means all equity interests of any kind, including common and preferred stock, options, warrants and other
agreements or rights to acquire the same (including any arising under or in connection with any employment agreement, incentive plan, benefit plan, or the like). 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated and rulings
issued thereunder. 
 “ERISA Affiliate” means, with respect to any entity, trade or business, any other entity, trade or
business that is a member of a group described in Section 414(b), (c), (m) or (o) of the Code or Section 4001(b)(1) of ERISA that includes the first entity, trade or business, or that is a member of the same “controlled
group” as the first entity, trade or business pursuant to Section 4001(a)(14) of ERISA. 
 “ERISA Plan” means an
“employee benefit plan” within the meaning of Section 3(3) of ERISA. 
 “Estates” means individually or
collectively, the estate or estates of each Debtor created under section 541 of the Bankruptcy Code. 
 “Exchange Act”
means the Securities Exchange Act of 1934, as amended. 
 “Excluded Matter” has the meaning set forth in the definition of
“Material Adverse Effect”. 
 “Exit Facility” has the meaning set forth in the Restructuring Term Sheet. 

“Exit Facility Documents” means the documents and agreements memorializing and otherwise related to the Exit Facility. 

“Expense Reimbursement Amount” means the dollar amount equal to the aggregate amount of all reasonable and documented out of
pocket costs, expenses and fees incurred by the Supporting Lenders or their respective Affiliates, in connection with evaluating, negotiating, documenting and performing the transactions contemplated by this Agreement, the Restructuring Term Sheet
and the Definitive Documents, including fees, costs and expenses of any professionals (including financial advisors, outside legal counsel, accountants, experts and consultants) retained by the Supporting Lenders or their respective Affiliates in
connection with 

  
 9 













 
or related to the authorization, preparation, investigation, negotiation, execution and performance of this Agreement, the transactions contemplated hereby, including the Chapter 11 Case and
other judicial and regulatory proceedings related to such transactions, which amount shall, subject to Bankruptcy Court approval, constitute an administrative expense priority claim under Section 503(b)(1)(A) of the Bankruptcy Code and shall be
payable as set forth in Section 9.3(b). 
 “FDA” means the United States Food and Drug
Administration. 
 “FDCA” means the U.S. Federal Food, Drug and Cosmetic Act of 1938, as amended
(21 U.S.C. § 301 et seq.). 
 “Final Order” means an Order which has not been stayed (or with respect
to which any stay has been lifted) and (i) as to which the time to file an appeal, a motion for rehearing or reconsideration (excluding any motion under Section 60(b) of the Federal Rules of Civil Procedure) or a petition for writ of
certiorari has expired and no appeal, motion, stay or petition is pending, or (ii) in the event that such an appeal or petition thereof has been sought, either (A) such Order shall have been affirmed by the highest court to which such
Order was appealed or certiorari shall have been denied, and the time to take any further appeal or petition of certiorari shall have expired or (B) such appeal, motion, stay or petition shall not have been granted and shall no longer be
pending and the time for seeking such appeal, motion, stay or petition shall have expired. 
 “GAAP” means United States
generally accepted accounting principles. 
 “Governmental Entity” means any U.S. or
non-U.S. governmental or regulatory authority, agency, commission, body, court or other legislative, executive, judicial, or administrative governmental entity at any level, or any agency, department or
instrumentality thereof. 
 “Guarantors” means (i) CVS/DMS Acquisition Corp., (ii) Nellix, Inc., (iii) TriVascular
Technologies, Inc., (iv) TriVascular, Inc., (v) Endologix Canada, LLC, (vi) TriVascular Sales LLC and (vii) RMS/Endologix Sideways Merger Corp. 

“Hazardous Substance” means any substance that is listed, classified or regulated pursuant to any Environmental Law. 

“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 

“Indebtedness” means, with respect to any Person, (a) all obligations for borrowed money, (b) all obligations
evidenced by bonds, debentures, notes or similar instruments, (c) all Indebtedness of others secured by any Encumbrance on owned or acquired property of the reference Person, whether or not the Indebtedness secured thereby has been assumed,
(d) all guarantees (and any other arrangement having the economic effect of a guarantee) of Indebtedness of others, (e) all obligations, contingent or otherwise, of such Person as an account party in respect of financial guaranties,
letters of credit, letters of guaranty, surety bonds and other similar instruments, (f) all obligations representing the deferred and unpaid purchase price of property (other than trade payables incurred in the ordinary course of business
consistent with 

  
 10 













 
past practice), (g) all obligations, contingent or otherwise, in respect of bankers’ acceptances and (h) net cash payment obligations of such Person under swaps, options,
derivatives and other hedging agreements or arrangements that will be payable upon termination thereof (assuming they were terminated on the date of determination). 

“Intellectual Property” means all intellectual property rights and proprietary rights of any kind or nature, including any
and all of the following arising in any jurisdiction of the world: (a) Patents; (b) Trademarks; (c) Trade Secrets; (d) Copyrights; (e) internet domain names; and (f) all applications for, and registrations of, any of the
foregoing. 
 “Inventory” means any and all raw materials, packaging and labelling materials, components, parts or other
supplies or inventories to which the Debtors have title that are in the possession of the Debtors or any third party and used or held for use in connection with any Product or related to the Business, whether located at any premises of the Debtors
or elsewhere. 
 “IRS” means the Internal Revenue Service of the United States. 

“IT Assets” means technology devices, computers, Software, servers, networks, workstations, routers, hubs, circuits,
switches, data communications lines, and all other information technology equipment and all associated documentation. 

“Knowledge of the Debtors” means the actual knowledge of the individuals set forth on Section 1.1
of the Company Disclosure Letter. 
 “Law” means any U.S. or non-U.S. federal,
state, provincial or local law, statute, code, ordinance, rule, regulation, Order, stipulation, award or common law requirement. 

“Lender Specified Representations” means the representations and warranties contained in the first sentence of
Section 6.1, Section 6.2 and Section 6.5. 

“Liability” means any debt, loss, liability, claim (including “claim” as defined in the Bankruptcy Code),
commitment, undertaking, damage, expense, fine, penalty, cost, royalty or obligation (including those arising out of any action, such as any settlement or compromise thereof or judgment or award therein), of any nature, whether known or unknown,
disclosed or undisclosed, express or implied, primary or secondary, direct or indirect, matured or unmatured, fixed, absolute, contingent, accrued or unaccrued, asserted or not asserted, liquidated or unliquidated, and whether due or to become due,
and whether in Contract, tort or otherwise. 
 “Material Adverse Effect” means any event, change, effect, condition, state
of facts or occurrence (regardless of whether such event, change, effect, condition, state of facts or occurrence constitutes a breach of any representation, warranty or covenant of the Debtors hereunder) which has had or would reasonably be
expected to have, individually or when considered together with any other events, changes, effects, conditions, states of facts or occurrences, (a) a material adverse effect on or a material adverse change in or to the business, results of
operations, financial condition, assets, or liabilities of the Company and its Subsidiaries (taken as a whole) or (b) a material adverse effect on the ability of the Debtors to consummate the Transactions or perform their obligations under this
Agreement or the Restructuring Term Sheet on a timely basis; provided, however, that a Material Adverse Effect shall not be deemed 

  
 11 













 
to include events, changes, effects, conditions, states of facts or occurrences arising out of, relating to or resulting from: (i) changes in the United States or foreign economies or
financial markets in general, (ii) general changes or developments in business, regulatory or macroeconomic conditions or trends that affect the industries and markets in which the Business operates, (iii) public announcement of this
Agreement or the Chapter 11 Cases, the public announcement or the consummation of the Restructuring and the Transactions, the commencement of the Chapter 11 Cases or the identity of the Supporting Lenders, (iv) any action or omission by the
Supporting Lenders in breach of this Agreement, (v) any action which is expressly requested in writing by a Supporting Lender, (vi) changes in any applicable Laws or applicable accounting regulations or principles or the enforcement or
interpretation thereof, (vii) any outbreak or escalation of hostilities or war or any act of terrorism or natural disaster or act of God (except to the extent related to any effects or conditions resulting from a disease or pandemic, including SARS-CoV-2 or COVID-19, or any governmental or other response thereto, in each case, whether or not involving the United States or any
other country in which the Company or any of its Subsidiaries operate) and (viii) any failure of the Business to meet any budgets, plans, projections or forecasts (internal or otherwise) or any decline in the trading price or trading volume of
the Company’s common stock or any change in the ratings or ratings outlook for the Company as a result of the commencement of the Chapter 11 Cases (each of clauses (i) through (viii), an “Excluded Matter”); provided
further that with respect to clauses (i), (ii), (vi) and (vii), such effects shall not be deemed to arise out of, relate to or result from an Excluded Matter to the extent the same disproportionately adversely affects the Company and its
Subsidiaries or the Business, in each case, taken as a whole, as compared to other similarly situated entities or businesses. 

“Milestones” means those Milestones set forth in Exhibit D. 

“Nasdaq” means the Nasdaq Stock Exchange. 

“OFAC” means the Office of Foreign Asset Control of the United States Department of the Treasury. 

“Order” means any order, injunction, judgment, decree, ruling, writ, assessment or arbitration award of, or entered, issued,
made or rendered by, a Governmental Entity, or any settlement agreement entered in connection therewith. 
 “Outside Date”
means October 5, 2020 at 11:59 p.m. Eastern Time. 
 “Patents” means patents and patent applications, invention
disclosures and rights in respect of utility models or industrial designs, including all related continuations, continuations-in-part, divisionals, reissues, re-examinations, renewals, revisions, supplementary protection certificates, substitutions, and extensions thereof. 

“Permits” means all licenses, permits, franchises, approvals, registrations, listings, authorizations, consents or orders of,
or filings with, any Governmental Entity. 
 “Permitted Encumbrance” means any (a) Encumbrances for Taxes not yet due
and payable or that are being contested in good faith through appropriate proceedings, (b) Encumbrance for assessments and other governmental charges or landlords’, carriers’, 

  
 12 













 
warehousemen’s, mechanics’, repairmen’s, workers’ or any similar Encumbrance incurred in the ordinary course of business consistent with past practice, in each case, for sums
not yet due and payable or due, but not delinquent or being contested in good faith by appropriate proceedings, (c) Encumbrance imposed or promulgated by applicable Law or any Governmental Entity with respect to real property, including zoning,
building, fire, health and Environmental Laws and similar regulations, (d) pledges or deposits in connection with workers’ compensation, unemployment insurance, social security and other similar legislation, (e) Encumbrance incurred
in the ordinary course of business consistent with past practice, in connection with workers’ compensation, unemployment insurance and other types of social security, (f) licenses, covenants not to sue or similar rights with respect to
Intellectual Property that are granted in the ordinary course of business and (g) those Encumbrances granted under the DIP Orders. 

“Person” means any individual, partnership, joint venture, limited liability company, corporation, trust, unincorporated
organization, group, governmental or regulatory authority, or any other legal entity or association, including the United States Trustee and any official or ad hoc committee formed in the Chapter 11 Cases. 

“Personal Information” means any information or data that alone, or together with any other data or information, identifies
any person or device, and any other personal information whose processing, security, collection, storage, use, disclosure, transfer or other exploitation is governed under any applicable Laws with respect to privacy or data protection. 

“Plan Supplement” means the documents and forms of documents, schedules and exhibits to the Plan, to be filed by the Debtors
no later than ten (10) calendar days before the deadline to vote on the Plan filed with the Bankruptcy Court (including any amendments or supplements thereto). Such documents shall be consistent with the terms of the Restructuring, the
Restructuring Term Sheet and the Plan and acceptable in form and substance to the Parties. 
 “Post-Restructuring
Insurance” means insurance (under one or more policies, including product liability insurance) that is acceptable to the Supporting Lenders in their sole discretion providing coverage for the risks of the Business and the Reorganized
Debtors and their properties and assets. 
 “Prepetition Security Agreements” means (i) the Amended and Restated
Guaranty and Security Agreement, dated August 9, 2018, among the Company, the Term Loan Agent and the Guarantors, as amended, supplemented, or otherwise modified from time to time in accordance with the terms thereof, (ii) the Guaranty and
Security Agreement, dated as of August 9, 2018, among the Company, the ABL Agent and the Guarantors, as amended, supplemented, or otherwise modified from time to time in accordance with the terms thereof, (iii) the Patent Security
Agreement, dated as of August 9, 2918, among the Company, Nellix, Inc., TriVascular, Inc. and the ABL Agent, as amended, supplemented, or otherwise modified from time to time in accordance with the terms thereof and (iv) the Trademark
Security Agreement, dated as of August 9, 2018, among the Company, TriVascular, Inc. and the ABL Agent, as amended, supplemented, or otherwise modified from time to time in accordance with the terms thereof. 

“Registered Intellectual Property” means all applications, registrations and filings for Intellectual Property that have been
registered or filed with or by, or are the subject of an 

  
 13 













 
application before, any Governmental Entity or internet domain name registrar, including the United States Patent and Trademark Office or United States Copyright Office, including issued Patents
and Patent applications, registered Trademarks and Trademark applications, registered Copyrights and Copyright applications, and internet domain name registrations. 

“Regulatory Authority” means any national or supranational Governmental Entity, including the FDA, with responsibility for
granting any license, registrations or approvals with respect to the Products. 
 “Representatives” means, when used with
respect to any Person, the directors, officers, partners, managers, employees, consultants, financial advisors, accountants, counsel, investment bankers and other agents, advisors and representatives of such Person and its Subsidiaries. 

“Sarbanes-Oxley Act” means the Sarbanes-Oxley Act of 2002, as amended. 

“SEC” means the United States Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended. 

“Software” means any and all (a) computer programs and other software, including software implementations of algorithms,
models, and methodologies, whether in source code, object code or other form, including libraries, subroutines and other components thereof, together with input and output formats; (b) computerized databases and other computerized compilations
and collections of data or information; (c) screens, user interfaces, command structures, report formats, templates, menus, buttons and icons; (d) descriptions, flow charts, architectures, development tools, and other materials used to
design, plan, organize and develop any of the foregoing; and (e) all documentation, including development, diagnostic, support, user and training documentation related to any of the foregoing. 

“Solicitation Materials” means, collectively, the Disclosure Statement and the other solicitation materials in respect of the
Plan. 
 “Subsidiary” means with respect to any Person, any corporation, limited liability company, partnership or other
organization, whether incorporated or unincorporated, of which (a) at least a majority of the outstanding shares of capital stock of, or other Equity Interests, having by their terms ordinary voting power to elect a majority of the board of
directors or others performing similar functions with respect to such corporation, limited liability company, partnership or other organization is directly or indirectly owned or controlled by such Person or by any one or more of its Subsidiaries,
or by such Person and one or more of its Subsidiaries or (b) with respect to a partnership, such Person or any other Subsidiary of such Person is a general partner of such partnership. 

“Takeover Statute” means any “fair price,” “moratorium,” “control share acquisition” or other
similar anti-takeover Law. 
 “Tax” or “Taxes” means any and all U.S. federal, state, local
and non-U.S. taxes, assessments, levies, duties, tariffs, imposts and other similar charges and fees imposed by any Governmental Entity, including income, franchise, windfall or other profits, gross receipts,


  
 14 













 
property, sales, use, net worth, capital stock, payroll, employment, social security, workers’ compensation, unemployment compensation, excise, withholding, ad valorem, stamp, transfer,
value-added, occupation, environmental, disability, real property, personal property, registration, alternative or add-on minimum, or estimated tax, including any interest, penalty, additions to tax and any
additional amounts imposed with respect thereto. 
 “Tax Return” means any return, filing, report, questionnaire,
information statement, claim for refund or declaration of estimated Taxes, including any schedule or attachment thereto or any amendment thereof, filed or required to be filed with any Taxing Authority in connection with the determination,
assessment or collection of any Tax, or the administration of any laws, regulations or administrative requirements relating to any Tax, including consolidated, combined and unitary tax returns. 

“Taxing Authority” means any U.S. federal, state, local or non-U.S. Governmental
Entity or authority exercising regulatory authority in respect of taxes or responsible for the imposition of any Tax. 
 “Trade
Secrets” means trade secrets and rights in confidential or proprietary information, inventions, know-how, discoveries, methods, processes, formulae, models, methodologies, drawings, prototypes,
designs, customer lists and supplier lists. 
 “Trademarks” means trademarks, trade names, service marks, trade dress,
certification marks, collective marks, d/b/a’s, symbols, design rights and other similar designations of origin, together with the goodwill associated with or symbolized by any of the foregoing. 

“Transaction Expenses” means all fees and expenses of the Prepetition Agents, the Supporting Lenders, and each of their
advisors, that are incurred in connection with the Restructuring. 
 “Transactions” means the acquisition of the Equity
Interests of the reorganized Debtors by the Supporting Lenders in accordance with the terms hereof and the Restructuring Term Sheet. 

Section 1.2 Terms Defined Elsewhere in this Agreement. The following terms are defined elsewhere in this Agreement, as indicated
below: 
  

			
	510(k)s	  	Section 5.19(b)
	AAA	  	Recitals
	ABL Agent	  	Preamble
	Agreement	  	Preamble
	Alternative Transaction Notice Period	  	Section 7.5(b)
	Bankruptcy Code	  	Recitals
	Bankruptcy Court	  	Recitals
	Business	  	Recitals
	Chapter 11 Cases	  	Recitals
	Company	  	Preamble
	Company Disclosure Letter	  	Article V


  
 15 














			
	Company Registered Intellectual Property	  	Section 5.11(a)
	Company SEC Documents	  	Section 5.6(a)
	Company Subsidiaries	  	Preamble
	Company Termination Event	  	Section 9.1(d)
	Consent	  	Section 5.4
	Debtor	  	Preamble
	Debtors	  	Preamble
	DIP Order	  	Recitals
	DIP Orders	  	Recitals
	DPLP	  	Preamble
	Effective Period	  	Section 3.1
	Endologix	  	Preamble
	Enforceability Limitations	  	Section 5.3
	Excluded Matter	  	Section 1.1
	FDA Law and Regulation	  	Section 5.19(a)
	FDCA Permits	  	Section 5.19(b)
	Final DIP	  	Recitals
	Financial Statements	  	Section 5.6(e)
	Insurance Policies	  	Section 5.21
	Interim DIP Order	  	Recitals
	Leases	  	Section 5.13(b)
	Material Contracts	  	Section 5.14(a)
	Notice	  	Section 10.8
	Other Motions	  	Section 4.1(b)
	Parties	  	Preamble
	Party	  	Preamble
	PDIII	  	Preamble
	PDIV	  	Preamble
	Petition Date	  	Recitals
	Plan	  	Recitals
	PMAs	  	Section 5.19(b)
	Prepetition Agents	  	Preamble
	Prepetition Agreement Claims	  	Section 3.3
	Prepetition Credit Agreement	  	Preamble
	Prepetition Facility Agreement	  	Preamble
	Prepetition Lenders	  	Preamble
	Privacy and Security Policies	  	Section 5.12(b)
	Products	  	Recitals
	Proposed Alternative Transaction	  	Section 7.5(a)
	Restructuring	  	Recitals
	Restructuring Term Sheet	  	Recitals
	Revised Supporting Lender Proposal	  	Section 7.5(c)
	Successor	  	Section 9.3(c)
	Superior Alternative Transaction	  	Section 7.5(b)
	Supporting Lender	  	Preamble
	Supporting Lender Termination Event	  	Section 9.1(b)


  
 16 














			
	Term Loan Agent	  	Preamble
	Term Loan Forbearance Agreement	  	Recitals
	Third Day Review Pleadings	  	Section 4.1(b)
	Transfer	  	Section 3.3
	Transferee	  	Section 3.3
	Transferee Joinder	  	Section 3.3

 ARTICLE II 

DEFINITIVE DOCUMENTS 

Section 2.1 Incorporation of Exhibits and Schedules. Each of the exhibits and schedules attached hereto, including the
Restructuring Term Sheet and all exhibits thereto, are expressly incorporated by reference and made part of this Agreement as if fully set forth herein. The Restructuring Term Sheet (including each of the exhibits thereto) sets forth the material
terms and conditions of the Plan and the Restructuring. Except as otherwise provided herein, neither this Agreement, the Restructuring Term Sheet nor any provision hereof or thereof may be modified, amended, waived or supplemented except in
accordance with Section 10.14. 
 Section 2.2 Definitive Documents. The Definitive Documents,
including any amendments, supplements or modifications thereof, shall contain terms and conditions consistent in all respects with this Agreement and the Restructuring Term Sheet. The Parties acknowledge and agree that (a) the Debtors provided
advance draft copies of the Plan and Disclosure Statement to counsel to the Supporting Lenders; and (b) they will each use commercially reasonable efforts to provide advance draft copies of all other Definitive Documents and other pleadings
(excluding pleadings of an administrative or ministerial nature) to counsel to the other Parties at least three (3) Business Days prior to the date when any Party intends to file such pleading or other document, if applicable; provided,
however, if circumstances reasonably prevent a Party from providing such drafts at least three (3) Business Days prior to filing, no Party shall be precluded from filing such Definitive Document and other pleadings, but such Party shall
use commercially reasonable efforts to provide a draft to the other Parties as soon as practicable under the circumstances prior to such filing; provided further, however, that the Debtors shall not be required to provide draft
copies of any declarations, retention applications, any fee statements, or any fee applications to counsel to the Supporting Lenders. 

ARTICLE III 

COMMITMENTS OF THE SUPPORTING LENDERS 

Section 3.1 Support of Restructuring. From the date of this Agreement and as long as this Agreement has not been terminated
pursuant to its terms (such period, the “Effective Period”), subject to the terms of this Agreement, each Supporting Lender severally agrees that it shall: 

(a) negotiate in good faith all Definitive Documents, reasonably agree to extensions of the Milestones to the extent required to accommodate
the Bankruptcy Court’s 

  
 17 













 
calendar, and comply with each of its other covenants and commitments set forth in this Agreement and the Restructuring Term Sheet; 

(b) provide prompt written notice to the Company between the date of this Agreement and the Effective Date of (i) the occurrence, or
failure to occur, of any event of which the occurrence or failure to occur would be reasonably likely to cause any Lender Specified Representations to be untrue or inaccurate in any respect or any other representation or warranty of the
Supporting Lenders contained in this Agreement to be untrue or inaccurate in any material respect, (ii) any material breach of any covenant of the Supporting Lenders contained in this Agreement, (iii) any event, condition, fact, or
circumstance that would make the timely satisfaction of any of the conditions set forth in Article VIII impossible or unlikely, (iv) the receipt of any written notice from any third party alleging that the consent of
such party is or may be required as a condition precedent to consummation of the Transactions or (v) the receipt of any written notice from any Governmental Entity that is material to the consummation of the Transactions; 

(c) (i) subject to receipt of the Disclosure Statement and other Solicitation Materials approved by the Disclosure Statement Order, timely
vote, or cause to be voted, all of its Claims to accept the Plan following the commencement of solicitation of votes for the Plan, by delivering their duly executed and completed ballots accepting the Plan; (ii) refrain from changing, revoking
or withdrawing (or causing such change, revocation or withdrawal of) such vote or consent; provided, however, that such vote may be revoked (and, upon such revocation, deemed void ab initio) by such Supporting Lender at any time
following the termination of this Agreement as to such Supporting Lender pursuant to the terms hereof; and (iii) not object to, delay, postpone, challenge, reject, oppose or take any other action that would reasonably be expected to prevent,
interfere with, delay or impede, directly or indirectly, the releases and exculpations set forth in the Plan and to the extent it is permitted to elect whether to opt in or opt out of any agreed upon releases or exculpations set forth in the Plan,
to elect to opt in, and not to elect to opt out of, the releases set forth in the Plan so long as such release may be revoked (and, upon such revocation, deemed void ab initio) by such Supporting Lender at any time following the termination
of this Agreement as to such Supporting Lender pursuant to the terms hereof; 
 (d) to the extent that a legal or structural impediment to
consummation of the Plan arises outside of the jurisdiction of the Bankruptcy Court, and such legal or structural impediment does not otherwise provide the Supporting Lenders with a right to terminate this Agreement, negotiate in good faith to
address any such impediment; and 
 (e) not: 

(i) object to, delay, postpone, challenge, reject, oppose or take any other action that would reasonably be expected to
prevent, interfere with, delay or impede, directly or indirectly, in any material respect, the approval, acceptance or implementation of the Restructuring on the terms set forth herein or in the Restructuring Term Sheet; 

(ii) object to or oppose, or support any other Person’s efforts to object to or oppose, any motions filed by the Company
that are consistent with this Agreement, 

  
 18 













 
including any request by the Company to extend its exclusive periods solely to file the Plan and solicit acceptances thereof; 

(iii) object to, or vote to reject, the Plan or any other Definitive Document that comports with this Agreement;
provided that the Supporting Lenders shall be entitled to object to or vote to reject the Plan or any Definitive Document on the basis that it does not comport with this Agreement; 

(iv) initiate any legal proceeding or enforce rights as holders of Claims that are inconsistent with, or that would reasonably
be expected to prevent or materially delay consummation of, the Restructuring; or 
 (v) take any actions where such taking
would be (A) inconsistent with this Agreement, the Restructuring Term Sheet or the Definitive Documents or (B) otherwise inconsistent with, or reasonably expected to prevent, interfere with or impede the implementation or consummation of,
the Restructuring. 
 Section 3.2 Rights of Supporting Lenders Unaffected. Nothing contained in this Agreement shall limit: 

(a) the rights of any Supporting Lender to appear as a party in interest in any matter to be adjudicated in order to be heard concerning any
matter arising in the Chapter 11 Cases, in each case, so long as the exercise of any such right is not inconsistent with such Supporting Lender’s obligations hereunder; 

(b) the ability of any Supporting Lender to purchase, sell, or enter into any transactions in connection with its Claims, subject to the terms
hereof and applicable Law; 
 (c) the ability of any Supporting Lender to assert or raise any objection in connection with any hearing in the
Bankruptcy Court so long as such objection is not inconsistent with such Supporting Lender’s obligations hereunder; 
 (d) any right of
any Supporting Lender to take or direct any action relating to the maintenance, protection, or preservation of any collateral so long as such action is not inconsistent with this Agreement; 

(e) subject to the terms hereof, any right of a Supporting Lender under (x) the Prepetition Credit Agreements, or that constitutes a
waiver or amendment of any provision of the Prepetition Credit Agreements, (y) the Prepetition Facility Agreements, or that constitutes a waiver or amendment of any provision of the Prepetition Facility Agreements or (z) any other
applicable agreement, instrument or document that gives rise to a Supporting Lender’s Claims or interests, as applicable, or that constitutes a waiver or amendment of any provision of any such agreement, instrument or document; 

(f) the ability of any Supporting Lender to consult with other Supporting Lenders or the Company; 

  
 19 













 (g) the ability of a Supporting Lender to enforce any right, remedy, condition, consent or
approval requirement under this Agreement, the DIP Orders or any of the other Definitive Documents; or 
 (h) the right of any Supporting
Lender to assert and receive distributions on any Claims held by such Supporting Lender (including Claims that do not arise under the Prepetition Credit Agreement, the Prepetition Facility Agreements, or the DIP Orders ). 

Section 3.3 Transfer of Claims. During the Effective Period, no Supporting Lender shall sell, contract to sell, give, assign,
participate, hypothecate, pledge, encumber, grant a security interest in, offer, sell any option or Contract to purchase, or otherwise transfer or dispose of, any economic, voting or other rights in or to, by operation of Law or otherwise (each, a
“Transfer”) all or any portion of the Claims arising under the Prepetition Credit Agreement or Prepetition Facility Agreements (“Prepetition Agreement Claims”) (including granting any proxies, depositing such
Prepetition Agreement Claims into a voting trust or entering into a voting agreement with respect to such Prepetition Agreement Claims); provided, however, that any Supporting Lender may Transfer any of its Prepetition Agreement Claims
to any Person (so long as such Transfer is not otherwise prohibited by any order of the Bankruptcy Court) that (i) agrees in writing, in substantially the form attached hereto as Exhibit C (a “Transferee
Joinder”), to be bound by the terms of this Agreement (each such transferee, a “Transferee”) or (ii) is a Supporting Lender; provided that upon any purchase, acquisition or assumption by any Supporting Lender of
any Prepetition Agreement Claims, such Prepetition Agreement Claims shall automatically be deemed to be subject to the terms of this Agreement. Subject to the terms and conditions of any order of the Bankruptcy Court limiting a Transfer, the
transferring Supporting Lender shall provide the Company and its counsel and the Prepetition Agents with a copy of any Transferee Joinder executed by such Transferee within one (1) Business Day following such execution. In the case of a
Transfer to a Person that is not a Supporting Lender, the Transfer shall only be effective upon execution and delivery of a Transferee Joinder in which event (A) the Transferee shall be deemed to be a Supporting Lender hereunder with respect to
all of its owned or controlled Prepetition Agreement Claims and (B) the transferor Party shall be deemed to relinquish its rights (and be released from its obligations) under this Agreement solely to the extent of such transferred Prepetition
Agreement Claims. With respect to Prepetition Agreement Claims held by the relevant Transferee upon consummation of a Transfer, such Transferee is deemed to make all of the representations and warranties of a Supporting Lender set forth in this
Agreement. Any Transfer of any Supporting Lender’s Prepetition Agreement Claim that does not comply with the foregoing shall be deemed void ab initio and the Company and each other Party shall have the right to enforce the voiding of
such Transfer. 
 ARTICLE IV 

COMMITMENTS OF THE COMPANY 

Section 4.1 Commitments of the Company. During the Effective Period, subject to the terms of this Agreement (including the terms
and conditions set forth in the Restructuring Term Sheet), including, for the avoidance of doubt, the Company’s rights regarding Alternative Transactions to the extent set forth herein, the Company agrees that it shall, and shall direct its
Subsidiaries and its and their respective Affiliates, to the extent applicable, to: 

  
 20 













 (a) (i) use commercially reasonable efforts to seek approval of the Plan and to
complete the Restructuring; (ii) prosecute and defend any appeals relating to the Confirmation Order; (iii) support and consummate the Restructuring in a timely manner in accordance with this Agreement, including to negotiate in good faith
all Definitive Documents, coordinate its activities with the other Parties hereto in respect of all matters concerning the implementation and consummation of the Restructuring and take any and all necessary and appropriate actions in furtherance of
this Agreement, (iv) use reasonable best efforts to comply with each Milestone as set forth in Exhibit D, including agreeing to the extension of such Milestones as required to accommodate the Bankruptcy Court’s calendar; and
(v) comply with each of its other covenants and commitments set forth in this Agreement and the Restructuring Term Sheet; 
 (b) provide
draft copies of (i) the Plan and Disclosure Statement to counsel to the Supporting Lenders at least ten (10) calendar days prior to filing with the Bankruptcy Court, (ii) subject to Section 2.2 hereof, the Plan Supplement, the
motion to approve the Disclosure Statement, the Solicitation Materials, any proposed Confirmation Order, any proposed amended version of the Plan or the Disclosure Statement, all “first day” pleadings (including forms of orders relating
thereto), and any other motions, draft orders, pleadings or briefs that are material to the Restructuring (collectively, the “Third Day Review Pleadings”) the Company intends to file with the Bankruptcy Court to counsel to the
Supporting Lenders at least two (2) Business Days prior to filing with the Bankruptcy Court, with all other motions, applications, proposed orders, pleadings and briefs (“Other Motions”) the Company intends to file with the
Bankruptcy Court to be provided to counsel to the Supporting Lenders no fewer than twenty-four (24) hours prior to filing with the Bankruptcy Court, and in each case, consult in good faith with such counsel regarding the form and substance of
any such proposed filing with the Bankruptcy Court or, to the extent such filing is required to be acceptable to the DIP Agent pursuant to this Agreement, not file such filing until it is acceptable to the DIP Agent; provided that
(x) the Debtors shall not be required to provide draft copies of any retention applications, any fee statements, any fee applications, or any supporting applications to counsel to the DIP Agent and (y) if the notice required by this
Section 4.1(b) with respect to the Third Day Review Pleadings and Other Motions is not reasonably practicable with respect to any document or pleading, the Debtors may provide such document or pleading as soon as reasonably
practicable; 
 (c) timely file a formal objection to any motion filed with the Bankruptcy Court by any Person seeking the entry of an order
directing the appointment of an examiner with expanded powers or a trustee, converting the Chapter 11 Cases to cases under chapter 7 of the Bankruptcy Code, dismissing the Chapter 11 Cases, modifying or terminating the Debtors’
exclusive right to file and/or solicit acceptances of a plan of reorganization or for relief that (x) is inconsistent with this Agreement or (y) would, or would reasonably be expected to, frustrate the purposes of this Agreement, including
by preventing the consummation of the Restructuring; 
 (d) timely file a formal written response in opposition to any objection filed with
the Bankruptcy Court by any Person with respect to the use of cash collateral pursuant to the DIP Orders or otherwise; 
 (e) timely file a
formal written response in opposition to any objection filed with the Bankruptcy Court by any Person with respect to the use of proceeds or with respect to 

  
 21 













 
any of the adequate protection granted to the Prepetition Lenders pursuant to the DIP Orders or otherwise; 

(f) consult with the Supporting Lenders with respect to the assumption or rejection of executory Contracts and unexpired leases of non-residential real property; 
 (g) pay all of the Transaction Expenses consistent with
Section 10.13 of this Agreement; 
 (h) provide prompt written notice to the Supporting Lenders between the date of
this Agreement and the Effective Date of (i) the occurrence, or failure to occur, of any event of which the occurrence or failure to occur would be reasonably likely to cause any Company Specified Representations to be untrue or inaccurate in
any respect or any other representation or warranty of the Company contained in this Agreement to be untrue or inaccurate in any material respect, (ii) any material breach of any covenant of the Company contained in this Agreement,
(iii) any event, condition, fact, or circumstance that would make the timely satisfaction of any of the conditions set forth in Article VIII impossible or unlikely, (iv) the receipt of any written notice from any
third party alleging that the consent of such party is or may be required as a condition precedent to consummation of the Transactions, (v) the receipt of any written notice from any Governmental Entity that is material to the consummation of
the Transactions, (vi) the receipt of any written notice of any proceeding commenced or threatened against the Company or its Subsidiaries that would otherwise affect in any material respect the Transactions, and (vii) the receipt of
any written notice of any offer to purchase any material assets of (or Equity Interests in) the Debtors; provided, however, that the delivery of any notice pursuant to this Section 4.1(h) shall not limit or
otherwise affect the remedies available to the party receiving such notice under this Agreement; 
 (i) not be in default under the DIP
Orders, subject to any applicable grace and cure periods; 
 (j) consult weekly (or more frequently as reasonably requested by the Supporting
Lenders) with the Supporting Lenders’ legal counsel and financial advisor regarding the Debtors’ strategic planning, discussions, negotiations, proposals, or agreements with respect to the Restructuring; and 

(k) not: 
 (i)
object to, delay, postpone, challenge, reject, oppose or take any other action that would prevent, interfere with, delay or impede, directly or indirectly, in any material respect, the approval, acceptance or implementation of the Restructuring on
the terms set forth in the Restructuring Term Sheet; 
 (ii) solicit, negotiate, propose, enter into, consummate, file with
the Bankruptcy Court, vote for or otherwise knowingly support, participate in or approve any Alternative Transaction; provided, however, that nothing in this Section 4.1(l) shall in any way limit the
Debtors’ rights regarding any Alternative Transaction in accordance with Section 7.5; 

  
 22 













 (iii) take any actions where such taking would be (A) inconsistent with
this Agreement, the Restructuring Term Sheet, the DIP Orders or the other Definitive Documents or (B) otherwise inconsistent with, or reasonably expected to prevent, interfere with, delay or impede the implementation or consummation of, the
Restructuring; 
 (iv) seek to amend or modify, or file a pleading seeking authority to amend or modify, the Definitive
Documents in a manner that is inconsistent with this Agreement; 
 (v) other than the Approved KEIP and the Approved KERP,
seek the payment of any amount pursuant to a key employee incentive plan, key employee retention plan or other similar payments during the pendency of the Chapter 11 Cases, unless consented to by the DIP Agent; or 

(vi) file or seek authority to file any pleading inconsistent with the Restructuring or the terms of this Agreement. 

Section 4.2 Rights of the Debtors Unaffected. Nothing contained in this Agreement shall limit: 

(a) the rights of any Debtor under any applicable bankruptcy, insolvency, or similar proceeding, including appearing as a party in interest in
any matter to be adjudicated in order to be heard concerning any matter arising in the Chapter 11 Cases, in each case, so long as the exercise of any such right is not inconsistent with the Company’s obligations hereunder; 

(b) the ability of any Debtor to assert or raise any objection in connection with any hearing in the Bankruptcy Court so long as such objection
is not inconsistent with the Company’s obligations hereunder; 
 (c) any right of any Debtor to take or direct any action relating to
the maintenance, protection, or preservation of such Debtor; so long as such action is not inconsistent with the Company’s obligations hereunder; or 

(d) the ability of any Debtor to enforce any right, remedy, condition, consent or approval requirement under this Agreement or any Definitive
Document. 
 ARTICLE V 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

Except as disclosed in (x) the Company SEC Documents publicly available prior to the date of this Agreement (but excluding any
predictive, cautionary or forward-looking disclosures contained under the captions “risk factors,” “forward-looking statements” or any similar precautionary sections and any other disclosures contained therein that are
predictive, cautionary or forward-looking in nature) or (y) the disclosure letter delivered by the Company to the Supporting Lenders simultaneously with the execution of this Agreement (the “Company 


  
 23 













 
Disclosure Letter”), the Company hereby represents and warrants to the Supporting Lenders as follows: 

Section 5.1 Qualification, Organization, Subsidiaries, etc. The Company and each of its Subsidiaries is a legal entity duly
organized, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of the jurisdiction of
its incorporation, organization or formation, as applicable, and has all requisite corporate or similar power and authority to own, lease and operate its properties and assets, and to carry on the Business as presently conducted by it. The Company
and each of its Subsidiaries is duly qualified to do business and is in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof)
as a foreign corporation or other entity in each jurisdiction where the ownership, leasing or operation of its assets or properties or the conduct of its portion of the Business requires such qualification, except where the failure to be so
qualified or, where relevant, in good standing (x) has not been and would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole) or (y) would not reasonably be expected to prevent or
materially hinder or delay any of the Transactions or the transactions contemplated by any of the Definitive Documents or affect the ability of the Company and its Subsidiaries to perform their obligations under this Agreement, the Restructuring
Term Sheet or any of the Definitive Documents. The Company does not own, directly or indirectly, any capital stock or other Equity Interests of any Person other than the Company Subsidiaries. Prior to the date of this Agreement, the Company has made
available to the Supporting Lenders a complete and accurate copy of the organizational documents of the Company and each of its Subsidiaries as in effect on the date of this Agreement. None of the Company or its Subsidiaries is in violation of any
of the provisions of its certificate of incorporation or bylaws (or equivalent organizational documents), in each case, except for violations that (i) have not been and would not reasonably be expected to be, individually or in the aggregate,
material to the Business (taken as a whole) and (ii) would not reasonably be expected to prevent or materially hinder or delay any of the Transactions or the transactions contemplated by any of the Definitive Documents or affect the ability of
the Company or its Subsidiaries to perform their respective obligations under this Agreement, the Restructuring Term Sheet or any of the Definitive Documents. 

Section 5.2 Capitalization. The authorized, issued and outstanding Equity Interests of the Company and each of its Subsidiaries is
set forth on Section 5.2 of the Company Disclosure Letter. All such Equity Interests were validly issued and are fully paid and nonassessable (except to the extent such concepts are not applicable under the applicable Law of the Company’s
or such Subsidiary’s jurisdiction of incorporation, formation or organization, as applicable). The Equity Interests of each of the Company’s Subsidiaries are owned beneficially and of record as set forth on Section 5.2 of the Company
Disclosure Letter, free and clear of any Encumbrances (other than any restrictions imposed by applicable Law) and free of preemptive rights, rights of first refusal, subscription rights or similar right of any Person and transfer restrictions (other
than transfer restrictions under applicable Law). Other than the Equity Interests reserved for issuance as set forth on Section 5.2 of the Company Disclosure Letter, none of the Company or its Subsidiaries has any Equity Interests reserved for
issuance. There are no existing (a) Equity Interests in the Company or any of its Subsidiaries other than the Equity Interests set forth on 

  
 24 













 
Section 5.2 of the Company Disclosure Letter, (b) without limitation to clause (a), rights, agreements or commitments of any character obligating the Company or any of its
Subsidiaries or any of their Affiliates, as applicable, to issue, transfer or sell any Equity Interests in the Company’s Subsidiaries or securities convertible into, exchangeable or exercisable for any of the foregoing, (c) contractual
obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any of the Equity Interests in the Company or the Company’s Subsidiaries or (d) voting trusts or similar agreements to which the Company or
any of its Subsidiaries is a party with respect to the voting of the Equity Interests set forth on Section 5.2 of the Company Disclosure Letter. 

Section 5.3 Corporate Authority. 

(a) The Company has all requisite corporate power and authority to execute and deliver, and to cause, directly or indirectly, any of the
Company’s Subsidiaries or their Affiliates to execute and deliver, as applicable, and, subject to the Company obtaining necessary Bankruptcy Court approvals from and after the Petition Date, to carry out the Restructuring and to perform its
respective obligations under this Agreement, each of the Definitive Documents and each other agreement, document or instrument contemplated hereby or thereby to which each such Person is a party. The execution and delivery of this Agreement, the
consummation of the Transactions by the Company and/or any of its Subsidiaries or their applicable Affiliates have been duly and validly authorized and approved by all requisite corporate or similar action of such Person (subject, from and after the
Petition Date, to the approval of the Bankruptcy Court). 
 (b) The Company further represents and warrants that the respective boards of
directors (or such other governing body) for the Company and each of its Subsidiaries has approved, by all requisite action, this Agreement and all of the Transactions, including the terms of the Restructuring set forth in the Restructuring Term
Sheet, and, subject to any necessary Bankruptcy Court approvals, no other corporate or similar proceedings (pursuant to any such Person’s organizational documents or otherwise) on the part of any such Person is necessary to authorize the
consummation of, and to consummate, the Transactions. 
 (c) The Board has taken all necessary action to ensure that none of the Supporting
Lenders will be an “interested stockholder” or prohibited from entering into or consummating a “business combination” or similar transaction with the Company (under Section 203 of the Delaware General Corporation Law or any
other applicable Takeover Statute), as a result of the execution of this Agreement or the consummation of the Transactions in the manner contemplated hereby. 

(d) Subject to the Company obtaining necessary Bankruptcy Court approvals from and after the Petition Date, this Agreement and each such other
document have been duly and validly executed and delivered by the Company and each of its applicable Subsidiaries and each of their applicable Affiliates, and, assuming the due authorization, execution and delivery of this Agreement and each such
other documents by the relevant Supporting Lender or its Affiliates, as applicable, constitute a legal, valid and binding agreement of the Company and each of its applicable Subsidiaries and each of their applicable Affiliates, enforceable against
each such Person in accordance with its terms, subject to applicable bankruptcy, insolvency, 

  
 25 













 
reorganization, fraudulent transfer, moratorium and similar laws affecting creditors’ rights generally and subject, as to enforceability, to general principles of equity, including
principles of commercial reasonableness, good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity) (the “Enforceability Limitations”). 

Section 5.4 Consents and Approvals. Except as expressly provided in this Agreement or in the Bankruptcy Code (including, with
respect to the Company from and after the Petition Date, the approval of the Bankruptcy Court) and Section 6.3, no consent, waiver, approval, Order, permit or authorization (including those with respect to state licensing
required to operate the Business) of, or declaration, filing or registration with, or notification to, any Governmental Entity, including in connection or compliance with the HSR Act (any of the foregoing, a “Consent”) is necessary
or required on the part of (a) the Company or any of its Subsidiaries in connection with the execution and delivery of this Agreement or any other agreement, document or instrument contemplated hereby to which the Company or any of its
Subsidiaries is a party and (b) any applicable Affiliate of the Company or any such Subsidiaries in connection with the execution and delivery of this Agreement or any other agreement, document or instrument contemplated hereby to which such
Person is a party, or in connection with, in each case of the foregoing clauses (a) and (b), the performance of such Person’s obligations hereunder and thereunder, or the consummation of the Transactions (with or without notice or lapse of
time, or both), except in each case of the foregoing clauses (a) and (b), (x) for such reports under the Exchange Act as may be required to be filed with the SEC in connection with this Agreement or the Transactions, (y) for such
Consents as may be required under applicable state securities or “blue sky” Laws and the securities Laws of any foreign country or the rules and regulations of Nasdaq and (z) for such other Consents which if not obtained or made,
(i) would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole) and (ii) would not reasonably be expected to prevent or materially hinder or delay any of the Transactions or the
transactions contemplated by any of the Definitive Documents or affect the ability of the Company or its Subsidiaries to perform their respective obligations under this Agreement, the Restructuring Term Sheet or any of the Definitive Documents. 

Section 5.5 No Violations. The execution or delivery of this Agreement or any agreement, document or instrument contemplated
hereby by the Company or any of its Subsidiaries or any of their applicable Affiliates, the performance of such Person’s obligations hereunder and thereunder, and the consummation of the transactions contemplated hereby or thereby, as
applicable, do not and will not (a) conflict with or result in any violation or breach of any provisions of the certificate of incorporation, bylaws or other organizational documents of any such Person, (b) with or without notice or lapse
of time or both, conflict with or result in any breach or violation of or constitute a default under, or give rise to a right of, or result in, termination, modification, cancellation, first offer, first refusal or acceleration of any obligation or
to the loss of a benefit under any Contract to which any such Person is a party or by or to which any of their respective properties, rights or assets, or the operations or conduct of the Business, are bound or subject or (c) conflict with or
violate any Order or Law applicable to any such Person or their respective properties, rights or assets, or the operations or conduct of the Business, except in the case of clauses (b) and (c), for any conflicts, breaches, violations, defaults,
rights or results that (x) have not been and would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole) or (y) would not reasonably be expected to prevent or materially hinder or
delay any of the Transactions or the 

  
 26 













 
transactions contemplated by any of the Definitive Documents or affect the ability of the Company or its Subsidiaries or their Affiliates, as applicable, to perform their obligations under this
Agreement, the Restructuring Term Sheet or any of the Definitive Documents. 
 Section 5.6 SEC Filings; Financial Statements.

 (a) The Company has timely filed with or furnished to the SEC all reports, schedules, forms, statements, prospectuses, registration
statements and other documents required to be filed with or furnished to the SEC by the Company since January 2, 2019 (collectively, together with any exhibits and schedules thereto and other information incorporated therein, the
“Company SEC Documents”). No Subsidiary of the Company is required to file any report, schedule, form, statement, prospectus, registration statement or other document with the SEC or any similar Governmental Entity in any
jurisdiction. 
 (b) As of its filing date (or, if amended or superseded by a filing prior to the date of this Agreement, on the date of such
amended or superseding filing), the Company SEC Documents filed or furnished prior to the date of this Agreement complied, and each Company SEC Document filed or furnished subsequent to the date of this Agreement will comply, in all material
respects with the applicable requirements of Nasdaq, the Securities Act, the Exchange Act and the Sarbanes-Oxley Act, as the case may be. 

(c) As of its filing date (or, if amended or superseded by a filing prior to the date of this Agreement, on the date of such amended or
superseding filing), each Company SEC Document filed or furnished prior to the date of this Agreement did not, and each Company SEC Document filed or furnished subsequent to the date of this Agreement will not, contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. 

(d) The Company is, and since January 2, 2019 has been, in compliance in all material respects with (i) the applicable provisions of
the Sarbanes-Oxley Act and (ii) the applicable listing and corporate governance rules and regulations of Nasdaq. 
 (e) The Company has
made available to the Supporting Lenders copies of the following financial statements (collectively the “Financial Statements”): (i) the audited consolidated balance sheet of the Company as of December 31, 2019 and the
related consolidated statements of operations, comprehensive income (loss), stockholders’ equity (deficit) and cash flows for the fiscal year then ended; and (ii) the unaudited consolidated balance sheet of the Company as of March 31,
2020 and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity (deficit) and cash flows for the three (3) months then ended. Subject to the notes thereto, the Financial Statements were
prepared, in all material respects, in conformity with GAAP and present fairly, in all material respects, the financial position of the Company (including its Subsidiaries) and its results of operations and cash flows as of the respective dates and
for the respective periods referred to in the Financial Statements (in the case of quarterly Financial Statements, subject to normal year-end adjustments). 

  
 27 













 (f) Since January 2, 2019, each of the principal executive officer and principal
financial officer of the Company (or each former principal executive officer and principal financial officer of the Company, as applicable) has made all certifications required by Rules 13a-14 and 15d-14 under the Exchange Act and Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC and Nasdaq, and the statements contained in any such certifications are
true and complete in all material respects as of the date on which they were made. 
 Section 5.7 No Undisclosed Liabilities.
There are no liabilities or obligations of the Company or any of its Subsidiaries of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise, that would be required by GAAP to be reflected on the
consolidated balance sheet of the Company and its Subsidiaries, other than (a) liabilities or obligations disclosed and provided for in the Financial Statements or in the notes thereto, (b) liabilities or obligations incurred in the
ordinary course of business consistent with past practice since March 31, 2020, (c) liabilities arising in connection with the Transactions, the Restructuring or the Chapter 11 Cases or (d) other liabilities or obligations that
(x) have not been and would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole), (y) would not reasonably be expected to prevent or materially hinder or delay any of the Transactions
or the transactions contemplated by any of the Definitive Documents or affect the ability of the Company or its Subsidiaries to perform their obligations under this Agreement, the Restructuring Term Sheet or any of the Definitive Documents or
(z) would not be discharged in the Chapter 11 Cases upon the Effective Date of the Plan. There are no off-balance sheet arrangements of any type required to be disclosed pursuant to Item 303(a)(4) of
Regulation S-K promulgated under the Securities Act that have not been so disclosed in the Company SEC Documents. 

Section 5.8 Absence of Certain Changes. Except to the extent arising out of or relating to the Chapter 11 Cases, this
Agreement or the Transactions, from January 2, 2019 through the date of this Agreement, the Business has been conducted in all material respects in the ordinary course of business consistent with past practice, and there has not been: 

(a) any material damage, destruction or other casualty loss with respect to any asset or property owned, leased or otherwise used by the
Company or its Subsidiaries, whether or not covered by insurance; 
 (b) any declaration, setting aside or payment of any dividend or other
distribution with respect to any shares of capital stock or other Equity Interests of the Company or its Subsidiaries (except for dividends or other distributions by any direct or indirect wholly owned Subsidiary to such Person or to any wholly
owned Subsidiary of such Person), or any repurchase, redemption or other acquisition by the Company or its Subsidiaries of any outstanding shares of capital stock or other Equity Interests of the Company or its Subsidiaries; 

(c) any material change in any method of accounting or accounting practice by the Company or its Subsidiaries; 

(d) (i) any material increase in the compensation payable or to become payable to the officers or employees of any of the Company or its
Subsidiaries or material 

  
 28 













 
increases in the benefits of such officers or employees (except for increases in the compensation of non-officer employees in the ordinary course of
business and consistent with past practice), (ii) any entrance into, adoption, material amendment or termination of any Debtor Plan (or any arrangement that would have been a Debtor Plan were it in effect as of the date of this Agreement) that
is or would be material to the Company and its Subsidiaries, taken as a whole or (iii) any actions taken by the Company and its Subsidiaries to accelerate the vesting or lapsing of restrictions or payment, or fund or in any other way secure the
payment, of any material compensation or benefits under any Debtor Plan, taken as a whole, except, in each case, to the extent required by applicable Laws; 

(e) any agreement to do any of the foregoing; or 

(f) any event, development, change or effect that has had or would reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect. 
 Section 5.9 Brokers or Finders. Other than Jefferies LLC, none of the Company or its Subsidiaries has
employed or engaged any investment banker, broker or finder who is entitled to any brokerage, finder’s or other fee or any commission in connection with this Agreement, the Restructuring Term Sheet, the Definitive Documents, the transactions
contemplated by this Agreement or any other agreement, document or instrument contemplated hereby or thereby based upon arrangements made by or on behalf of the Company or its Subsidiaries or any of their Affiliates. 

Section 5.10 Litigation. 

(a) Except (x) as set forth on Section 5.10(a) of the Company Disclosure Letter and (y) for the Chapter 11 Cases, there are
no Causes of Action pending or, to the Knowledge of the Debtors, threatened, and no facts (including any defects or quality issues related to any former or current Products) exist which would give rise to any such Causes of Action, against any of
the Company or its Subsidiaries or any of their respective properties, rights or assets, or that involves or relates to any of the Transactions or the operations or conduct of the Business, except those which have not been and would not reasonably
be expected to be, individually or in the aggregate, material to the Company or any of its Subsidiaries. None of the Company, any of its Subsidiaries, any applicable Affiliates or the Business is subject to any outstanding Order, and there are no
judgments or decrees of or settlement agreements with, any Governmental Entity, except those which have not been and would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries. 

(b) There is no (i) settlement agreement involving the Company or any of its Subsidiaries that impedes or limits the Company or any of its
Subsidiaries to operate in the ordinary course of business, as currently conducted, or (ii) Cause of Action of any nature pending or, to the Knowledge of the Debtors, threatened against any Person who has a contractual right or a right to
indemnification from the Company or any of its Subsidiaries related to facts and circumstances existing prior to the date of this Agreement, nor is there any reasonable basis therefor, in each case, except as would not reasonably be expected to be,
individually or in the aggregate, material to the Company of any of its Subsidiaries. 

  
 29 













 (c) Notwithstanding the foregoing, no representation or warranty is made under this
Section 5.10 in respect of any (i) Intellectual Property matters, which are addressed in Section 5.11, (ii) employee benefits matters, which are addressed in
Section 5.16, (iii) environmental matters, which are addressed in Section 5.18, (iv) healthcare regulatory matters, which are addressed in Section 5.19 or
(v) Tax matters, which are addressed in Section 5.20. 
 Section 5.11 Intellectual Property. 

(a) Section 5.11(a) of the Company Disclosure Letter sets forth a true and complete list, as of the date hereof, of all Registered
Intellectual Property that is (i) owned or purported to be owned by, or (ii) exclusively licensed to, the Company or any of its Subsidiaries (the “Company Registered Intellectual Property, setting forth (A) the legal and
record owner(s), (B) the registration or application number (as applicable), (C) the registration or application date (as applicable) and (D) the jurisdiction in which such item is registered or pending or, with respect to internet domain
names, the applicable internet domain name registrar. All Company Registered Intellectual Property is subsisting and (other than Registered Intellectual Property constituting applications) valid, and to the Knowledge of the Debtors, enforceable.
There is no, and since January 1, 2017, there has been no, Cause of Action or notice of any objection or claim asserted in writing or, to the Knowledge of the Debtors, threatened by any Person, seeking to cancel, materially limit, or challenge
the ownership, validity or enforceability of any Company Registered Intellectual Property, and the Company and each of its applicable Subsidiaries have made timely payment of all registration, maintenance, renewal and filing fees required with
respect to the Company Registered Intellectual Property. 
 (b) The Company and its Subsidiaries, taken together, solely and exclusively own
all Company Intellectual Property free and clear of any Encumbrances (other than Permitted Encumbrances), and no other Person has any joint ownership interest in or to any of the Company Intellectual Property. None of the Company Intellectual
Property is subject to any Order adversely affecting or restricting the validity or enforceability thereof, or any of the Company’s or any of its Subsidiaries’ ownership or use thereof. 

(c) The Company and its Subsidiaries own or have sufficient and valid right to use all Intellectual Property that is material to or necessary
for the conduct of the Business as currently conducted and as currently planned to be conducted, all of which material Intellectual Property rights shall survive the consummation of the transactions contemplated by this Agreement without termination
or substantial acceleration of any obligation thereunder. 
 (d) Except as has not resulted in, and would not reasonably be expected to
result in, material liability for the Company or any of its Subsidiaries or disruption to the Business, since the January 1, 2017, (i) neither (A) the conduct of the Business, nor (B) the administration, use, supply, manufacture,
import, marketing, commercialization or other exploitation of any of the Products (including by any applicable customers, suppliers or contractors), has infringed, misappropriated, or violated any Intellectual Property of any other Person,
(ii) to the Knowledge of the Debtors, no Person has infringed, misappropriated, or otherwise violated any Company Intellectual Property and (iii) none of the Company nor any of its Subsidiaries have sent or received any written claim,
notice, demand to license, or similar 

  
 30 













 
communication alleging or suggesting any infringement, misappropriation, or other violation of the type described in clauses (i) or (ii) of this Section 5.11(d).

 (e) The Company and each of its Subsidiaries have, at all times since January 1, 2017, taken commercially reasonable efforts to
protect the confidentiality of all material Trade Secrets that are owned, used or held by any of the Company or any of its Subsidiaries, and no such material Trade Secrets have been used by, disclosed to or otherwise discovered by any Person except
pursuant to valid and enforceable non-disclosure and confidentiality agreements (or obligations arising by operation of Law) that have not, to the Knowledge of the Debtors, been breached by such Persons. 

(f) Each Person who contributed to the development or creation of any material Company Intellectual Property used in or held for use in the
conduct of the Business as currently conducted or as currently planned to be conducted has executed a valid and enforceable agreement containing an irrevocable present assignment conveying to one or more of the Company or its Subsidiaries (or has
otherwise assigned by operation of Law) all of such Person’s right, title and interest in and to such Intellectual Property. To the Knowledge of the Debtors, no current or former employee or contractor of any of the Company or any of its
Subsidiaries retains or claims to retain any ownership interest in or to any Company Intellectual Property. 
 (g) None of the Company
Intellectual Property is subject to any obligation under any Contract or other present or contingent obligation as a result of being developed using any funding or support from, or any arrangement with, a Governmental Entity or nonprofit
organization. 
 Section 5.12 Data Privacy and Cybersecurity; IT Assets. 

(a) The Company IT Assets are sufficient for the current and currently anticipated needs of the Business, and since January 1, 2017, there
has been no unauthorized access to or unauthorized use of any (i) IT Assets owned, used or held for use by the Company or any of its Subsidiaries, (ii) information of, or collected, stored or processed by or on behalf of, the Company or
its Subsidiaries and collected, stored or processed by such IT Assets, or (iii) confidential or proprietary information of the Company or any of its Subsidiaries, in each case, in a manner that, individually or in the aggregate, has resulted in
or would reasonably be expected to result in material liability or disruption of the Business; provided that the foregoing representations with respect to IT Assets owned or controlled by third-party service providers are given only to the
Knowledge of the Debtors. None of the IT Assets owned, used or held for use by the Company or any of its Subsidiaries since January 1, 2017 contain or make available any material disabling codes or instructions, spyware, Trojan horses, worms,
viruses or other software routines that facilitate or cause unauthorized access to, or disruption, impairment, disablement, or destruction of, Software, data or other materials. 

(b) The Company and each of its Subsidiaries have established and implemented appropriate written policies and organizational, physical,
administrative and technical measures regarding privacy, cyber security and data security, and are no less protective than (i) reasonable practices in the industry or (ii) any written commitments of the Company or


  
 31 













 
any of its Subsidiaries (such policies and measures, collectively, the “Privacy and Security Policies”). 

(c) At all times since January 1, 2017, except as has not resulted in, and would not reasonably be expected to result in, individually or
in the aggregate, material liability or an obligation to notify any Governmental Entity, (i) the Company and each of its Subsidiaries have complied in all respects with all of their respective Privacy and Security Policies and contractual
obligations, and with all applicable Laws (including (A) the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their implementing
regulations and agency guidance and (B) any other applicable state or foreign privacy laws), in each case, regarding Personal Information, including with respect to the collection, use, storage, processing, transmission, transfer (including
cross-border transfers), disclosure and protection of Personal Information and (ii) no Person has gained unauthorized access to or misused any Personal Information collected, stored or processed by or on behalf of, the Company or any of its
Subsidiaries. 
 Section 5.13 Real Property Leases. 

(a) None of the Company or any of its Subsidiaries owns any real property. 

(b) Section 5.13(b) of the Company Disclosure Letter sets forth a complete and correct list, as of the date of this Agreement, of each
Contract pursuant to which the Company or any of its Subsidiaries leases, subleases or occupies any real property (the “Leases”). None of the Company or any of its Subsidiaries has subleased, licensed or otherwise granted any Person
the right to use or occupy any real property subject to a Lease or any material portion thereof. Each Lease is valid, binding and in full force and effect, subject to the Enforceability Limitations, and no uncured default of a material nature on the
part of the Company or any of its Subsidiaries or, to the Knowledge of the Debtors, the landlord thereunder exists with respect to any Lease. The Company and its Subsidiaries have good and valid leasehold interests in or contractual rights to use or
occupy, subject to the terms of the applicable Lease, each real property subject to the Leases. 
 Section 5.14 Material
Contracts. 
 (a) Section 5.14(a) of the Company Disclosure Letter contains a complete and correct list, as of the date of this
Agreement, of each Contract described below in this Section 5.14(a) under which the Company or any of its Subsidiaries has any current or future rights, responsibilities, obligations or liabilities (in each case, whether
contingent or otherwise) or to which the Company or any of its Subsidiaries is a party or to which any of their respective properties or assets is subject, other than the Debtor Plans listed on Section 5.16(a) of the Company Disclosure Letter
(all Contracts of the type described in this Section 5.14(a), whether or not set forth on Section 5.14(a) of the Company Disclosure Letter, being referred to herein as the “Material Contracts”): 

  
 32 













 (i) requires expenditures by the Company or any of its Subsidiaries
involving consideration in excess of two hundred and fifty thousand dollars ($250,000) in the next twelve (12)-month period; 

(ii) provides for payments to be received by the Company or any of its Subsidiaries in excess of two hundred and fifty thousand
dollars ($250,000) in any twelve (12)-month period; 
 (iii) relates to the incurrence by the Company or any of its
Subsidiaries of any Indebtedness or any capitalized lease obligations in excess of fifty thousand dollars ($50,000); 
 (iv)
relates to the acquisition or disposition outside the ordinary course of business of any assets or any business, or any capital stock of any enterprise (whether by merger, sale or purchase of stock, sale or purchase of assets or otherwise) entered
into in the past three (3) years, in each case, in excess of two hundred and fifty thousand dollars ($250,000); 
 (v)
relates to the future acquisition or disposition of any material assets or properties (whether by merger, sale or purchase of stock, sale or purchase of assets or otherwise, including any option to acquire, sell, lease or license any material assets
or properties of the Business), other than (A) in the ordinary course of business consistent with past practice, (B) as contemplated by this Agreement, the Restructuring Term Sheet or any Definitive Document or (C) to the extent
permitted under applicable Law, any non-disclosure or similar agreement entered into in connection with the process by which the Company or any of its Subsidiaries, any of their respective Affiliates or any
Representatives of any of the foregoing solicited, discussed or negotiated strategic alternatives prior to the date of this Agreement (including the Transactions or any other transaction prior to the date of this Agreement); 

(vi) is a joint venture, profit-sharing, partnership, collaboration, co-promotion,
commercialization, research, development or other similar agreement involving the sharing of profits or expenses (other than clinical trial agreements, contract manufacturing agreements or other similar subcontracting arrangements entered into in
the ordinary course of business); 
 (vii) is a Lease; 

(viii) (A) may require the Supporting Lenders to pay milestones, royalties or other contingent payments based on any
research, testing, development, regulatory filings or approval, sale, distribution, marketing, commercial manufacture or other similar occurrences, developments, activities or events with respect to any Product, in each case, which payments are in
an amount having an expected value in excess of fifty thousand dollars ($50,000) during the fiscal year ending December 31, 2020 or any fiscal year thereafter or (B) grants to any Person a right of first refusal, right of first
negotiation, option to purchase, option to license, or any other similar rights with respect to any Product; 

  
 33 













 (ix) requires the Company or any of its Subsidiaries to purchase from a
third Person their total requirements of any products or services; 
 (x) with any Governmental Entity; 

(xi) (A) limits or purports to limit, in any material respect, the freedom of the Business to engage or compete in any
line of business or with any Person or in any geographic area, (B) contains exclusivity or “most favored nation” obligations in favor of any Person other than the Company or its Subsidiaries or restrictions to which the Business is
subject or (C) contains any other provisions restricting or purporting to restrict the ability of the Company or its Subsidiaries to sell, market, distribute, promote, manufacture, develop, commercialize, or test or research the Products,
directly or indirectly through third parties (other than any such restrictions or purported restrictions that have a de minimis effect on the Business); 

(xii) is a material Contract pursuant to which the Company or any of its Subsidiaries grants or receives any license, covenant
not to sue or similar right with respect to, or governs or restricts the development, ownership, use, practice or enforcement of, any Intellectual Property (other than non-exclusive licenses to use Software on
standardized terms that are generally commercially available); 
 (xiii) relates to sales and distribution activities
conducted by a third-party wholesaler or distributor that are material to the Business; 
 (xiv) relates to the ongoing
supply or manufacturing of clinical and commercial quantities of any of the Products, the termination of which would reasonably be expected to be material to the Business (taken as a whole); 

(xv) other than the Contracts described in Section 5.14(a)(iii), under which the Company or any of
its Subsidiaries or any of their Affiliates have borrowed or loaned money, or any note, bond, indenture, mortgage or any guarantee of such indebtedness, in each case, relating to amounts in excess of one hundred thousand dollars ($100,000); 

(xvi) relates to any settlement or stipulation of any Cause of Action against the Company or any of its Subsidiaries by any
other Person, other than settlement agreements for cash that do not exceed twenty-five thousand dollars ($25,000) individually as to any such settlement or stipulation (excluding amounts paid by insurers) or one hundred thousand dollars ($100,000)
individually as to any such settlement or stipulation (including any amounts paid by insurers), entered into since January 2, 2019; and 

(xvii) provides for indemnification of any officer, director or employee of the Company or its Subsidiaries or any of their
Affiliates other than in the ordinary course of business. 
 (b) True and complete copies of each Material Contract, together with all
amendments, modifications or supplements thereto, as of the date of this Agreement have been 

  
 34 













 
made available to the Supporting Lenders. None of the Company or any of its Subsidiaries has received any written notice of termination (or intent to terminate) with respect to a Material
Contract from any third Person party to such Material Contract. No event has occurred which, with the passage of time or the giving of notice, or both, would constitute a default under or a violation of any Material Contract or would cause the
acceleration of any obligation of the Company or any of its Subsidiaries or their applicable Affiliates or the creation of an Encumbrance (other than Permitted Encumbrances) upon any assets or properties of the Company or any of its Subsidiaries,
except for such events that have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. To the Knowledge of the Debtors, as of the date of this Agreement, no other party to any Material
Contract is in breach of or default under the terms of any Material Contract where such breach or default has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Each Material Contract is a
valid, binding and enforceable obligation of the applicable the Company or its applicable Subsidiaries or their applicable Affiliates party thereto and, to the Knowledge of the Debtors, of each other party thereto, and is in full force and effect,
subject to the Enforceability Limitations. 
 Section 5.15 Compliance with Laws; Anticorruption; Permits; Trade
Compliance. 
 (a) The Company and each of its Subsidiaries and their applicable Affiliates are and since January 1, 2015 have been,
operating the Business in compliance with all applicable Laws and Orders, including (i) applicable Law administered or enforced by the FDA, (ii) applicable Laws relating to the Medicare and Medicaid programs, any other federal healthcare
programs, and any state healthcare or health insurance programs, (iii) applicable Laws relating to healthcare fraud and abuse, including the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)),
the federal False Claims Act (31 U.S.C. §§ 3729 et seq.), the federal Stark Law (42 U.S.C. § 1395nn), the federal False Statements Statute (42 U.S.C. § 1320a-7b(a)), the Exclusion Laws (42
U.S.C. § 1320a-7), the Beneficiary Inducement Statute (42 U.S.C. § 1320a-7a(a)(5)), and the Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), (iv) applicable Laws relating to billing or claims for reimbursement submitted to any government or third-party payor, (v) applicable Laws relating to fraudulent, abusive or unlawful practices
connected in any way with the provision or marketing of healthcare items or services, (vi) Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h) and similar gift and disclosure applicable Laws of any
Governmental Entity, and (vii) applicable Laws relating to health information privacy, including the Health Insurance Portability and Accountability Act of 1996 (including its underlying rules) and the Health Information Technology for Economic
and Clinical Health Act of 2009, in each case of clauses (i)-(vii), except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Since January 1, 2015, none of the Company or
its Subsidiaries, nor any of their applicable Affiliates, has received any written notice of or, to the Knowledge of the Debtors, been charged with any violation of any Laws, except as has not been and would not reasonably be expected to be,
individually or in the aggregate, material to the Business (taken as a whole). 
 (b) The Company and its Subsidiaries and their applicable
Affiliates are and, since January 1, 2015, have been operating the Business in compliance with the U.S. Foreign Corrupt Practices Act and any other applicable anticorruption Laws, except where the failure to be in compliance has not been and
would not reasonably be expected to be, individually or in the 

  
 35 













 
aggregate, material to the Business (taken as a whole). Since January 1, 2015, none of the Company or its Subsidiaries, nor any of their applicable Affiliates, nor to the Knowledge of the
Debtors, any officer or director of any of the foregoing, while acting at the direction of such Person, (a) has made, paid or received any unlawful bribes, kickbacks or other similar payments or (b) has made or paid any contributions,
directly or indirectly, to a domestic or foreign political party or candidate, except, in each case, as has not been and would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole). 

(c) The Company and its Subsidiaries have all Business Permits, except where the failure to possess such Business Permits has not had and would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. None of the Company or its Subsidiaries, nor any of their applicable Affiliates, is in default or violation of any term, condition or provision of any
Business Permit, except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect, all Business Permits are valid and in full force and effect, subject to the Enforceability Limitations, and, to the Knowledge of the Debtors, no condition exists that with notice or lapse of time or both would constitute a
default of any term, condition or provision of any such Business Permits to which the Company or any of its Subsidiaries or any of their applicable Affiliates is a party. Since January 1, 2015, none of the Company or its Subsidiaries, or any of
their applicable Affiliates, has received any written notice of any Cause of Action or investigation relating to the revocation, nonrenewal, suspension or modification of any Business Permit, except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect. 
 (d) Except as has not and would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect, the Company and its Subsidiaries and their applicable Affiliates are and, since January 1, 2015, have been in compliance with: (i) all Laws or regulations regarding the
importation of goods, including the U.S. import laws administered by U.S. Customs and Border Protection; and (ii) all other applicable Laws, including the Export Administration Regulations administered by the U.S. Department of Commerce. Except
as has not and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, none of the Company or its Subsidiaries nor any of their applicable Affiliates, nor to the Knowledge of the Debtors, any officer or
director of any of the foregoing Persons, is (i) a person or entity with whom U.S. persons or entities are restricted from doing business under regulations of OFAC (including those named on OFAC’s Specially Designated and Blocked Persons
List) or under any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), regulation, or other governmental
action, (ii) a “specially designated global terrorist” or other person listed in Appendix A to Chapter V of 31 C.F.R., as the same has been from time to time updated and amended or (iii) a person either
(A) included within the term “designated national” as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515 or (B) designated under Sections 1(a), 1(b), 1(c) or 1(d) of Executive Order No. 13224, 66 Fed.
Reg. 49079 (published September 25, 2001) or a person similarly designated under any related enabling legislation or any other similar executive orders. 

  
 36 













 Section 5.16 Employee Benefit Matters. 

(a) Section 5.16(a) of the Company Disclosure Letter sets forth a complete and correct list of each Debtor Plan that is an “employee
benefit plan” within the meaning of Section 3(3) of ERISA, an equity-based plan, or an executive employment or severance plan or agreement. With respect to each such Debtor Plan, the Company has made available to the Supporting Lenders, to
the extent applicable, accurate and complete copies of (i) the Debtor Plan document, including any amendments thereto, and all related trust documents, insurance contracts or other funding vehicles, (ii) a written description of such
Debtor Plan if such plan is not set forth in writing, (iii) the most recently prepared actuarial report, (iv) all material correspondence to or from any Governmental Entity received since January 1, 2017 with respect to any Debtor
Plan, (v) the most recent summary plan description together with any summaries of all material modifications thereto, (vi) the most recent IRS determination or opinion letter issued and (vii) the most recent annual report (Form 5500
or 990 series and all schedules and financial statements attached thereto). 
 (b) (i) Each Debtor Plan (including any related trusts)
has been established, operated and administered in accordance with its terms and in compliance with applicable Law, including ERISA and the Code, (ii) all contributions or other amounts payable by the Company or any of its Subsidiaries with
respect to any Debtor Plan in respect of current or prior plan years have been paid or accrued in accordance with generally accepted accounting principles and (iii) there are no pending or, to the Knowledge of the Debtors, threatened claims
(other than routine claims for benefits) or proceedings by a Governmental Entity by, on behalf of or against any Debtor Plan or any trust related thereto which would reasonably be expected to result in any material liability to the Company or any of
its Subsidiaries. 
 (c) Each ERISA Plan that is intended to be qualified under Section 401(a) of the Code has been determined by the
IRS to be qualified under Section 401(a) of the Code and, to the Knowledge of the Debtors, nothing has occurred that would adversely affect the qualification or tax exemption of any such Debtor Plan. With respect to any ERISA Plan, none of the
Company or any of its Subsidiaries has engaged in a transaction in connection with which the Company or any of its Subsidiaries reasonably could be subject to either a civil penalty assessed pursuant to Section 409 or 502(i) of ERISA or a tax
imposed pursuant to Section 4975 or 4976 of the Code. 
 (d) None of the Company or any of its Subsidiaries nor any ERISA Affiliate has,
within the six (6)-year period prior to the date of this Agreement, ever maintained, established, sponsored, participated in, contributed to, or been obligated to contribute to, or otherwise incurred any obligation or liability (including any
contingent liability) under any “multiemployer plan” (as defined in Section 3(37) of ERISA) or any plan that is subject to Section 302 or Title IV of ERISA or Section 412 of the Code. None of the Company or any of its
Subsidiaries nor any ERISA Affiliate has any actual or potential withdrawal liability for any complete or partial withdrawal (as defined in Sections 4203 and 4205 of ERISA) from any multiemployer plan. 

(e) Except as required by applicable Law, no Debtor Plan provides retiree or post-employment medical, disability, life insurance or other
welfare benefits to any Person, and 

  
 37 













 
none of the Company or any of its Subsidiaries has any obligation to provide such benefits. To the extent that the Company or any of its Subsidiaries sponsors such plans, the Company or the
applicable Subsidiary has reserved the right to amend, terminate or modify at any time each Debtor Plan that provides retiree or post-employment disability, life insurance or other welfare benefits to any Person. 

(f) Neither the execution and delivery of this Agreement, shareholder or other approval of this Agreement or the Plan nor the consummation of
the transactions contemplated by this Agreement, whether alone or in combination with any other event, will (i) entitle any current or former employee, director, officer or independent contractor of the Company or any of its Subsidiaries to
severance pay or any material increase in severance pay, (ii) accelerate the time of payment or vesting or materially increase the amount of compensation due to any such current or former employee, director, officer or independent contractor,
(iii) directly or indirectly cause the Company or any of its Subsidiaries to transfer or set aside any assets to fund any material benefits under any Debtor Plan, (iv) otherwise give rise to any material liability under any Debtor Plan or
(v) limit or restrict the right to merge, materially amend, terminate or transfer the assets of any Debtor Plan on or following the Effective Date. 

(g) Neither the Company nor any of its Subsidiaries has any obligation to provide, and no Debtor Plan or other agreement provides any
individual with the right to, a gross up, indemnification, reimbursement or other payment for any excise or additional taxes, interest or penalties incurred pursuant to Section 409A or Section 4999 of the Code or due to the failure of any
payment to be deductible under Section 280G of the Code. 
 (h) No Debtor Plan is maintained outside the jurisdiction of the United
States or covers any employees or other service providers of the Company or any of its Subsidiaries who reside or work outside of the United States. 

Section 5.17 Labor Matters. 

(a) The Company has made available to the Supporting Lenders a true, correct and complete list, by employee identification number, of all
employees employed by the Company and its Subsidiaries on the date of this Agreement, identifying as to each a job title, years of service, current amount or rate of compensation and location of employment. 

(b) As of the date of this Agreement, neither the Company nor any of its Subsidiaries is a party to, or bound by, any collective bargaining
agreement or other agreement with any labor union or like organization, and to the Knowledge of the Debtors, there are no activities or proceedings by any individual or group of individuals, including representatives of any labor organizations, or
labor unions, to organize any employees of the Company or any of its Subsidiaries. As of the date of this Agreement, there is no pending or, to the Knowledge of the Debtors, threatened labor strike, slowdown, lockout or work stoppage, unfair labor
practice or other labor dispute, or labor arbitration or grievance. 
 (c) The Company and each of its Subsidiaries is in compliance in all
material respects with all applicable Laws respecting labor, employment and employment practices, terms and conditions of employment, wages and hours, and occupational safety and health. Neither the 


  
 38 













 
Company nor any of its Subsidiaries has incurred any liability or obligation under the Worker Adjustment and Retraining Notification Act of 1988, as amended, and the regulations promulgated
thereunder or any similar state, local or foreign Law relating to plant closings or mass layoffs that remains unsatisfied. 

Section 5.18 Environmental Matters. 

(a) Except as has not and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect: 

(i) each real property operated by the Company or any of its Subsidiaries and used in the conduct of their respective
businesses: (i) is in compliance with all applicable Environmental Laws, except as has not and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; (ii) is not the subject of any pending
written notice from any Governmental Entity alleging the violation of any applicable Environmental Law; (iii) is not currently subject to any Orders arising under any Environmental Law; and (iv) has not had any emissions or discharges of
Hazardous Substances except as permitted under applicable Environmental Laws; 
 (ii) no order, decree, settlement or lien is
pending or, to the Knowledge of the Debtors, threatened, against the Company or any of its Subsidiaries relating to Liability under any Environmental Law that has not been remedied as of the date of this Agreement; and 

(iii) there are no other circumstances or conditions that would reasonably be expected to result in any claims, liability,
investigations, costs or restrictions on the ownership, use, or transfer of the Company’s or any of its Subsidiaries’ assets or properties in connection with any Environmental Law. 

(b) The Company has made available to the Supporting Lenders copies of all environmental reports, studies, assessments, sampling data,
memoranda and other information in its possession. 
 Section 5.19 FDA and Related Regulatory Matters. 

(a) Each of the Company and its Subsidiaries is conducting and has at all times conducted its business and operations in compliance with the
FDCA, 21 U.S.C. §301 et. seq., and all applicable regulations promulgated by the FDA (collectively, “FDA Law and Regulation”), and the Laws and regulations of other similar Governmental Entities that regulate the safety and
effectiveness of medical device and biological products. Each Medical Device, as that term is defined in 21 U.S.C. § 321(h) of the FDCA, that is manufactured, tested, distributed and/or marketed by the Company and its Subsidiaries, is being
manufactured, tested, distributed and/or marketed by the Company and its Subsidiaries in material compliance with applicable FDA Law and Regulation and the Laws and regulations of other similar Governmental Entities that regulate the safety and
effectiveness of medical device and biological products, including those relating to (i) good manufacturing practices, (ii) regulatory approvals or clearances to 

  
 39 













 
market Medical Devices, (iii) investigational studies, (iv) labeling, (v) record keeping, and (vi) filing of reports to FDA or other similar Governmental Entities. 

(b) Section 5.19(b) of the Company Disclosure Letter sets forth a list of all registrations, clearances and approvals issued under the
FDCA (“FDCA Permits”) and held exclusively by the Company or its Subsidiaries, including pre-market notifications under section 510(k) of the FDCA (21 U.S.C. § 360(k))
(“510(k)s”) and pre-market approval applications and associated supplements approved in accordance with 21 U.S.C. § 360(e) (“PMAs”). Such listed FDCA Permits are the only
FDCA Permits that are required for the Company or its Subsidiaries to conduct the Business in the United States. Each such FDCA Permit is in full force and effect and no suspension, revocation, cancellation or withdrawal of such FDCA Permit is
threatened and there is no basis for believing that such FDCA Permit will be suspended, revoked, cancelled or withdrawn. The Company or its Subsidiaries exclusively own all 510(k)s and PMAs for the Products, and the FDA has not threatened in writing
to suspend or revoke any such 510(k)s or PMAs. 
 (c) The Company and its Subsidiaries have paid all fees pursuant to the Medical Device User
Fee Amendments and complied with the Device Facility Registration of Establishment regulations and all devices of the Company and its Subsidiaries are appropriately listed with FDA. 

(d) Except as set forth on Section 5.19(d) of the Company Disclosure Letter, none of the Company nor any of its Subsidiaries have received
any notice or communication from the FDA or other similar Governmental Entities alleging noncompliance with any applicable FDA Law and Regulation and the Laws and regulations of other similar Governmental Entities that regulate the safety and
effectiveness of medical device and biological products. The Company and its Subsidiaries are not subject to any enforcement, regulatory or administrative proceedings by the FDA or other similar Governmental Entities and no such proceedings have
been threatened. There is no civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, untitled letter, proceeding or request for information pending against the Company or its
Subsidiaries, and neither the Company nor any of its Subsidiaries have any liability (whether actual or contingent) for failure to comply with any FDA Law and Regulation or the Laws and regulations of other similar Governmental Entities that
regulate the safety and effectiveness of medical device and biological products. There is no act, omission, event, or circumstance that would give rise to or lead to any such action, suit, demand, claim, complaint, hearing, investigation, notice,
demand letter, warning letter, proceeding or request for information or any such liability. There has not been any violation of any FDA Law and Regulation and the Laws and regulations of other similar Governmental Entities that regulate the safety
and effectiveness of medical device and biological products in product development efforts, submissions, record keeping and reports to FDA or other similar Governmental Entity that could require or lead to investigation, corrective action or
enforcement, regulatory or administrative action. There are no civil or criminal proceedings relating to the Company, its Subsidiaries or any Company or Subsidiary employee which involve a matter within or related to the FDA’s jurisdiction or
the jurisdiction of other similar Governmental Entities that regulate the safety and effectiveness of medical device and biological products whether within the United States or abroad. 

  
 40 













 (e) Neither the Company nor any of its Subsidiaries have not introduced into commercial
distribution any products manufactured by or on behalf of the Company and its Subsidiaries or distributed any products on behalf of another manufacturer which were upon their shipment adulterated or misbranded in violation of 21 U.S.C.
§ 331 or the Laws and regulations of other similar Governmental Entities that regulate the safety and effectiveness of medical device and biological products. 

(f) Since January 1, 2015, there has been no false or misleading information or significant omission in any applications, submissions, or
reports submitted by the Company or any of its Subsidiaries to any Governmental Entity, including the FDA, in violation of any applicable Law or Order. 

(g) Except as identified in Section 5.19(g) of the Company Disclosure Letter, (i) all clinical,
pre-clinical and other studies and tests conducted by, or on behalf of or sponsored by the Company or any of its Subsidiaries have been and are being conducted in accordance with applicable Law, including the
FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 812, (ii) no investigational device exemption filed by or on behalf of the Company or any of its Subsidiaries with the FDA has been terminated or suspended by any
Regulatory Authority and (iii) no Regulatory Authority has commenced, or threatened in writing to initiate, any Cause of Action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing clinical
investigation conducted or proposed to be conducted by or on behalf of the Company or any of its Subsidiaries. There have been no developments in connection with any clinical, pre-clinical or other studies or
tests conducted by, or on behalf of or sponsored by the Company or its Subsidiaries that would reasonably be likely to (x) impact any Governmental Entity’s approval of a Product, (y) create the possibility of the reclassification of
any Product or (z) jeopardize the continuation of such studies or tests. 
 (h) No officer, employee or agent of the Company or any of
its Subsidiaries has: (i) made any untrue statement or fraudulent statement to the FDA or any other Governmental Entity; (ii) failed to disclose a fact required to be disclosed to the FDA or any other Governmental Entity; or
(iii) committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide a basis for the FDA or any other Governmental Entity to invoke its policy respecting “Fraud, Untrue Statements of Material
Facts, Bribery, and Illegal Gratuities,” as set forth in 56 Fed. Reg. 46191 (September 10, 1991). No officer, employee or agent of the Company or its Subsidiaries has been convicted of any crime or engaged in any conduct for which
debarment is mandated or permitted by 21 U.S.C. § 335a. No officer, employee or agent of the Company or its subsidiaries has been convicted of any crime or engaged in any conduct for which such person or entity could be excluded from
participating in the federal health care programs under Section 1128 of the Social Security Act or any similar law or regulation. Neither the Company nor any of its Subsidiaries is a party to a Corporate Integrity Agreement with the U.S.
Department of Health and Human Services Office of Inspector General or has had any reporting obligations pursuant to any settlement, deferred prosecution, consent decree, or any other agreement entered into with any Governmental Entity. 

(i) With respect to each Product sold by the Company or its Subsidiaries, the Company and its Subsidiaries have complied with (i) all
applicable contractual commitments applicable to such Product, (ii) all product specifications applicable to such Product and (iii) all 

  
 41 













 
express and implied warranties applicable to each such Product, in each case of clauses (i)-(iii). The standard warranty terms for the Company and its Subsidiaries have been made available to the
Supporting Lenders. 
 (j) All material product issues, incidents and complaints have been suitably investigated, documented and managed, any
applicable problem or legally required reports have been filed with FDA and other similar Governmental Entities that regulate the safety and effectiveness of medical device and biological products and any necessary recalls have been fully
implemented. 
 Section 5.20 Taxes. 

(a) The Company and each of its Subsidiaries has prepared (or caused to be prepared) and timely filed (taking into account valid extensions of
time within which to file) all material Tax Returns required to be filed by any of them, and all such filed Tax Returns (taking into account all amendments thereto) are accurate and complete in all material respects. 

(b) All material Taxes owed by the Company and each of its Subsidiaries that are due and payable (whether or not shown as due on a Tax Return)
have been timely paid or, if not yet due and payable, adequately reserved against in accordance with GAAP. 
 (c) No deficiency for any
amount of material Taxes has been proposed or asserted in writing or assessed by any Taxing Authority against the Company or any of its Subsidiaries that remains unpaid or unresolved. 

(d) The Company and each of its Subsidiaries has not received written notice of any pending Causes of Action, examinations or proposed
adjustments in respect of any material amount of Taxes of the Company or any of its Subsidiaries. 
 (e) All material Taxes required to be
withheld or collected by the Company or any of its Subsidiaries have been withheld and collected and, to the extent required by applicable Law, timely paid to the appropriate Taxing Authority, and all forms required to be filed with respect thereto
have been properly completed and timely filed. 
 (f) There are no material Encumbrances for Taxes on any of the assets of the Company or any
of its Subsidiaries, other than Encumbrances for Taxes or other governmental charges not yet due and payable or that are being contested in good faith by appropriate proceedings and are reflected on or specifically reserved against or otherwise
disclosed in any consolidated balance sheet included in the Financial Statements. 
 (g) Neither the Company nor any of its Subsidiaries has
been a “controlled corporation” or a “distributing corporation” in any distribution occurring during the two (2)-year period ending on the date of this Agreement that was purported or intended to be governed by Section 355
of the Code (or any similar provision of state, local or non-U.S. Law). 
 (h) No claim has been
received, or is expected by the Company to be received, with respect to the Company or any of its Subsidiaries from a Taxing Authority in a jurisdiction where such entity does not file Tax Returns that it is or may be subject to taxation


  
 42 













 
by, or required to file any Tax Return in, that jurisdiction which claim has not since been resolved. 

(i) Neither the Company nor any of its Subsidiaries has been a member of an affiliated group of corporations filing a consolidated federal
income Tax Return (other than a group the common parent of which is the Company) or has had any liability for the Taxes of any person (other than the Company or any of its Subsidiaries) under U.S. Treasury Regulation
Section 1.1502-6 (or any similar provision of any state, local or non-U.S. Law), as a transferee or successor. 

(j) Neither the Company nor any of its Subsidiaries is a party to, or is bound by, or has any obligation under, any Tax sharing Contract, Tax
allocation agreement, Tax indemnity obligation or similar agreement or practice other than (A) Contracts solely among the Company and/or its Subsidiaries and (B) customary Tax indemnification provisions in Contracts entered into in the
ordinary course of business, the primary purpose of which does not relate to Taxes. 
 (k) Neither the Company nor any of its Subsidiaries
has currently in effect any waiver of any statute of limitations in respect of Taxes or any agreement to any extension of time with respect to the filing of a Tax Return or an assessment or deficiency for Taxes (other than pursuant to extensions of
time to file Tax Returns obtained in the ordinary course of business). 
 (l) Neither the Company nor any of its Subsidiaries has
participated in any “listed transaction” within the meaning of U.S. Treasury Regulations Section 1.6011-4(b). 

(m) The Company has made available to the Supporting Lenders accurate and complete copies of any private letter ruling requests, closing
agreements or gain recognition agreements with respect to Taxes of the Company or any of its Subsidiaries requested or executed in the past five (5) years. 

Section 5.21 Insurance. The insurance policies maintained by the Company and its Subsidiaries (the “Insurance
Policies”) provide full and adequate coverage for all normal risks incident to the business of the Company and its Subsidiaries and their respective properties and assets, except for any such failures to maintain such insurance policies
that have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Each of the Insurance Policies is in full force and effect and all premiums due with respect to all Insurance Policies have
been paid, except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

Section 5.22 No Other Representations; No Reliance. 

(a) Notwithstanding the delivery or disclosure to the Supporting Lenders, any of their Affiliates or any of their respective Representatives of
any documentation or other information (including any financial projections or other supplemental data) or anything to the contrary in this Agreement, except for the representations and warranties expressly contained in this
Article V (in each case, as qualified by the Company Disclosure Letter), (i) neither the Company nor any other Person has made or is making, and each of the Company and its Affiliates expressly disclaims, any
representation or warranty of any kind or nature, whether 

  
 43 













 
express or implied, at Law or in equity, with respect to the accuracy or completeness of any information provided or made available to the Supporting Lenders by or on behalf of the Company in
connection with or related to this Agreement, the transactions contemplated hereby, or the completeness of any information provided in connection therewith and (ii) the Company hereby expressly disclaims any such other representations and
warranties. 
 (b) Except for the representations and warranties contained in Article VI, the Company acknowledges
that it (a) has had an opportunity to conduct any and all due diligence with respect to the Supporting Lenders and any of their respective Subsidiaries in connection with the transactions contemplated hereby, (b) has relied solely upon its
own independent review, investigation, and/or inspection of any documents in connection with the transactions contemplated hereby and (c) did not rely upon any written or oral statements, representations, promises, warranties, or guaranties
whatsoever, whether express, implied, by operation of Law, or otherwise regarding any Supporting Lender or any Subsidiaries or Affiliates thereof, or with respect to any other information provided or made available to the Company or any of its
Subsidiaries in connection with the transactions contemplated hereby, or the completeness of any information provided in connection therewith. 

ARTICLE VI 

REPRESENTATIONS AND WARRANTIES OF THE SUPPORTING LENDERS 

Each applicable Supporting Lender represents and warrants to the Company (as to itself only, severally and not jointly), as follows: 

Section 6.1 Qualification; Organization. Each Supporting Lender is a legal entity duly organized, validly existing and in good
standing (with respect to jurisdictions that recognize such concept) under the laws of its jurisdiction of organization and has all requisite corporate or similar power and authority to own, lease and operate its properties and assets and to carry
on its business as presently conducted, except where the failure to be so existing and in good standing or to have such power and authority would not, individually or in the aggregate, materially impair or materially delay its ability to perform its
obligations under this Agreement. Each Supporting Lender is qualified to do business and is in good standing (with respect to jurisdictions that recognize such concept) as a foreign corporation or other entity in each jurisdiction where the
ownership, leasing or operation of its assets or properties or conduct of its business requires such qualification, except where the failure to be so qualified or, where relevant, in good standing, would not, individually or in the aggregate,
materially impair or materially delay its ability to perform its obligations under this Agreement. 
 Section 6.2 Corporate
Authority. Each Supporting Lender has the requisite power and authority to execute and deliver (or to cause one or more of its Affiliates to execute and deliver, as applicable) this Agreement and each other agreement, document or instrument
contemplated hereby or thereby to which it is a party and, subject to the Company obtaining necessary Bankruptcy Court approvals from and after the Petition Date, to carry out the Restructuring and to perform its obligations hereunder and
thereunder. The execution and delivery of this Agreement and each other agreement, document or instrument contemplated hereby or thereby to which it is a party and the consummation of the Transactions have been duly authorized by all


  
 44 













 
requisite corporate or similar action on the part of each Supporting Lender. This Agreement and each other agreement, document or instrument contemplated hereby or thereby to which it is a party
has been duly and validly executed and delivered (subject, from and after the Petition Date, to the approval of the Bankruptcy Court). Subject to the Company obtaining necessary Bankruptcy Court approvals from and after the Petition Date, this
Agreement and each such other document have been duly and validly executed and delivered by each of the applicable Supporting Lenders and each of their applicable Affiliates, and, assuming the due authorization, execution and delivery by the other
Parties or their Affiliates, as applicable, constitute a legal, valid and binding agreement of each of the Supporting Lenders and their Affiliates, as applicable, enforceable against such Person in accordance with its terms, subject to the
Enforceability Limitations. 
 Section 6.3 Consents and Approvals. Except as expressly provided in this Agreement or in the
Bankruptcy Code and Section 5.4, no consent, waiver, approval, Order, permit or authorization (including those with respect to state licensing required to operate the Business) of, or declaration, filing or registration
with, or notification to, any Governmental Entity, including in connection or compliance with the HSR Act, is necessary or required on the part of (a) any Supporting Lender in connection with the execution and delivery of this Agreement or any
other agreement, document or instrument contemplated hereby to which such Supporting Lender is a party and (b) any applicable Affiliate of any Supporting Lender in connection with the execution and delivery of any agreement, document or
instrument contemplated hereby to which such Person is a party, or in connection with, the performance of such Person’s obligations hereunder and thereunder, or the consummation of the Transactions (with or without notice or lapse of time, or
both), except in each case of the foregoing clauses (a) and (b), for immaterial Consents. 
 Section 6.4 No Violations. The
execution or delivery of this Agreement or any agreement, document or instrument contemplated hereby or thereby by any Supporting Lender or any of its applicable Affiliates, the performance of such Person’s obligations hereunder and thereunder,
and the consummation of the transactions contemplated hereby or thereby, as applicable, do not and will not (a) conflict with or result in any violation or breach of any provisions of the certificate of incorporation, bylaws or other
organizational documents of any such Person or (b) conflict with or violate any Order or Law applicable to any Supporting Lender or its properties, rights or assets, except in the case of clause (b), for any conflicts or violations that
(y) have not been and would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole) and (z) would not reasonably be expected to prevent or materially hinder or delay any of the
Transactions or the transactions contemplated by any of the Definitive Documents or affect the ability of the Supporting Lenders or their Affiliates, as applicable, to perform their obligations under this Agreement, the Restructuring Term Sheet or
any of the Definitive Documents. 
 Section 6.5 Brokers. Other than Houlihan Lokey Capital, Inc., the Supporting Lenders have
not employed or engaged any investment banker, broker or finder who is entitled to any brokerage, finder’s or other fee or any commission from the Supporting Lenders in connection with this Agreement, the Restructuring Term Sheet, the
Definitive Documents, the transactions contemplated by this Agreement or any other agreement, document or instrument contemplated hereby or thereby based upon arrangements made by or on behalf of the Supporting Lenders or any of their Affiliates.


  
 45 













 Section 6.6 Ownership of Claims. Each Supporting Lender represents and warrants
to each of the other Parties that, as of the date such Party executes this Agreement or a Transferee Joinder, as applicable: (a) it either (i) is the sole legal and beneficial owner of the aggregate principal amount of Claims set forth on
its signature page, in each case, free and clear of any pledge, lien, security interest, charge, claim, proxy, voting restriction, right of first refusal or other limitation on disposition of any kind, in each case, that is reasonably expected to
adversely affect such Supporting Lender’s performance of its obligations contained in this Agreement or (ii) has full power and authority to vote the Claims (including Prepetition Agreement Claims held through participations or interests
or pursuant to permissible transfers) set forth on its signature page; (b) it has full power and authority to vote on and consent to all matters concerning the Claims set forth on its signature page and to exchange, assign, and transfer such
Claims; (c) it is either (i) a qualified institutional buyer as defined in Rule 144A of the Securities Act or (ii) an institutional accredited investor as defined in Rule 501(a)(l), (2), (3) or (7) under the Securities
Act; (d) any securities acquired by a Supporting Lender in connection with the Restructuring described herein and in the Restructuring Term Sheet will be acquired for investment purposes and not with a view to distribution in violation of the
Securities Act; and (e) it has made no prior assignment, sale, participation, grant, conveyance or other Transfer of, and has not entered into any other agreement to assign, sell, participate, grant, convey or otherwise Transfer, in whole or in
part, any portion of its right, title, or interests in any Claims that is inconsistent with the representations and warranties of such Supporting Lender herein or would render such Supporting Lender otherwise unable to comply with this Agreement and
perform its obligations hereunder. 
 Section 6.7 No Other Representations; No Reliance. 

(a) Notwithstanding the delivery or disclosure to the Company, any of its Affiliates or any of their respective Representatives of any
documentation or other information (including any financial projections or other supplemental data) or anything to the contrary in this Agreement, except for the representations and warranties expressly contained in this
Article VI, (i) neither the Supporting Lenders nor any other Person has made or is making, and each of the Supporting Lenders and its Affiliates expressly disclaims, any representation or warranty of any kind or
nature, whether express or implied, at Law or in equity, with respect to the accuracy or completeness of any information provided or made available to the Company by or on behalf of the Supporting Lenders in connection with or related to this
Agreement, the transactions contemplated hereby, or the completeness of any information provided in connection therewith and (ii) the Supporting Lenders hereby expressly disclaim any such other representations and warranties. 

(b) Except for the representations and warranties contained in Article V, the Supporting Lenders acknowledge that
they (a) have had an opportunity to conduct any and all due diligence with respect to the Company and any of its respective Subsidiaries in connection with the transactions contemplated hereby, (b) have relied solely upon their own
independent review, investigation, and/or inspection of any documents in connection with the transactions contemplated hereby and (c) did not rely upon any written or oral statements, representations, promises, warranties, or guaranties
whatsoever, whether express, implied, by operation of Law, or otherwise regarding the Company or any Subsidiaries or Affiliates thereof, or with respect to any other information provided or made available to such Supporting Lender in connection with


  
 46 













 
the transactions contemplated hereby, or the completeness of any information provided in connection therewith. 

ARTICLE VII 

COVENANTS 

Section 7.1 Interim Operations. 

(a) The Company covenants and agrees as to itself and its Subsidiaries that, during the Effective Period, except (i) as otherwise
expressly required or contemplated by this Agreement or the Restructuring Term Sheet, (ii) as required by applicable Law (including the Bankruptcy Code) or (iii) as consented to in writing by the DIP Agent (which consent shall not be
unreasonably withheld, conditioned or delayed), (x) the Business shall be conducted in the ordinary course of business consistent with past practice and in accordance with applicable Law and (y) the Company and its Subsidiaries shall use their
respective commercially reasonable efforts to preserve intact the Business and their relationship with customers, suppliers, distributors, wholesalers, retailers, employees and Governmental Entities. 

(b) Without limiting the generality of, and in furtherance of, the foregoing, during the Effective Period, except (x) as otherwise
expressly required or contemplated by this Agreement or the Restructuring Term Sheet, (y) as required by applicable Law (including the Bankruptcy Code) or (z) as consented to in writing by the DIP Agent (which consent shall not be
unreasonably withheld, conditioned or delayed), the Company shall not, and shall not permit any of its Subsidiaries to, directly or indirectly: 

(i) amend the certificate of incorporation, bylaws or other organizational documents of the Company or its Subsidiaries; 

(ii) merge or consolidate the Company or any of its Subsidiaries with any other Person, or restructure, reorganize or
completely or partially liquidate the Company or any of its Subsidiaries or otherwise enter into any agreements providing for the sale of their respective material assets, operations or business; 

(iii) acquire assets outside of the ordinary course of business from any other Person; 

(iv) issue, sell, pledge, dispose of, grant, transfer, encumber, or authorize the issuance, sale, pledge, disposition, grant,
transfer or encumbrance of, any shares of capital stock or Equity Interests of the Company or any of its Subsidiaries (other than the issuance of shares by a wholly owned Subsidiary of the Company to the Company or another wholly owned Subsidiary),
or securities convertible or exchangeable into or exercisable for any shares of such capital stock or Equity Interests, or any options, warrants or other rights of any kind to acquire any of the foregoing; 

(v) incur, create or assume any Encumbrance (other than Permitted Encumbrances) on any properties or assets, tangible or
intangible, of the Company or any of its Subsidiaries; 

  
 47 













 (vi) (A) incur, assume or guarantee any Indebtedness or capitalized
lease obligations or issue any debt securities or (B) make any loans, advances, guarantees or capital contributions to, or investments in, any other Person; 

(vii) declare, set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with
respect to any of its capital stock or Equity Interests (except for dividends paid by any direct or indirect wholly owned Subsidiary to the Company or to any other direct or indirect wholly owned Subsidiary) or enter into any agreement with respect
to the voting of its capital stock or Equity Interests (other than this Agreement); 
 (viii) reclassify, split, combine,
subdivide or redeem, purchase or otherwise acquire, directly or indirectly, any of its capital stock or Equity Interests or securities convertible or exchangeable into or exercisable for any of the foregoing; 

(ix) except in accordance with the Budget (as defined in the DIP Orders), make or authorize any capital expenditure; 

(x) enter into any Contract that would have been a Material Contract had it been entered into prior to this Agreement; 

(xi) other than in the ordinary course of business, cancel or terminate (other than, for the avoidance of doubt, any expiration
in accordance with its terms), or modify or amend in any material respect, or waive any material rights under, any Material Contract; 

(xii) make any material changes with respect to material accounting policies or procedures, except as required by changes in
applicable Law or GAAP; 
 (xiii) settle or compromise any (A) Cause of Action (other than settlements involving only
unsecured claims with an allowed amount of less than one hundred thousand dollars ($100,000)), or (B) Patent-related Cause of Action involving any of the Company Intellectual Property; 

(xiv) transfer, assign, sell, lease, grant any license (other than non-exclusive
licenses granted in the ordinary course of business) with respect to, or, to the extent within the control of the Company or any of its Subsidiaries, abandon or permit to lapse, any material Company Intellectual Property; 

(xv) terminate or fail to renew any material Business Permit; 

(xvi) other than in the ordinary course of business, sell, pledge, dispose of, transfer or authorize the sale, pledge,
disposition or transfer of any assets or properties of the Company or its Subsidiaries; 
 (xvii) grant any material
licenses, sublicenses, covenants not to assert or similar rights with respect to any assets or properties, whether tangible or intangible, of the Company or its Subsidiaries; 

  
 48 













 (xviii) fail to use commercially reasonable efforts to maintain the
Insurance Policies or to renew or replace the Insurance Policies following their termination; 
 (xix) except as required
pursuant to the terms of any Debtor Plan in effect as of the date of this Agreement, the Approved KEIP or the Approved KERP, (A) increase in any manner the compensation, consulting fees, incentive, bonus, retirement, welfare, fringe or other
benefits, severance or termination pay of any employee or independent contractor, (B) become a party to, establish, adopt, amend, commence participation in or terminate any Debtor Plan or any arrangement that would have been a Debtor Plan had
it been entered into prior to this Agreement, (C) grant any new awards, or amend or modify the terms of any outstanding awards, under any Debtor Plan, (D) take any action to accelerate the vesting or lapsing of restrictions or payment, or
fund or in any other way secure the payment, of compensation or benefits under any Debtor Plan, (E) change any actuarial or other assumptions used to calculate funding obligations with respect to any Debtor Plan that is required by applicable
Law to be funded or change the manner in which contributions to such plans are made or the basis on which such contributions are determined, except as may be required by GAAP, (F) forgive any loans or issue any loans (other than routine travel
advances issued in the ordinary course of business) to any employee, (G) hire any employee or engage any independent contractor (who is a natural person) other than the engagement of independent contractors to fill vacancies or staff currently
existing or contemplated projects to the extent not currently staffed or (H) terminate the employment of any officer other than for cause other than any officer who was provided with written notice of termination prior to the date of this
Agreement and who is listed on Section 7.1(b)(xix) of the Company Disclosure Letter; 
 (xx) become a party to,
establish, adopt, amend, commence participation in or terminate any collective bargaining agreement or other agreement with a labor union, works council or similar organization; 

(xxi) (A) change in any material respect any material method of accounting of the Company or its Subsidiaries for Tax
purposes; (B) enter into any agreement with any Taxing Authority (including a “closing agreement” under Code Section 7121) with respect to any material Tax or Tax Returns of the Company or its Subsidiaries; (C) surrender a
right of the Company or its Subsidiaries to a material Tax refund; (D) change an accounting period of the Company or its Subsidiaries with respect to any material Tax; (E) file an amended Tax Return; (F) change or revoke any material
election with respect to Taxes; (G) make any material election with respect to Taxes that is inconsistent with past practice; (H) file any Tax Return that is inconsistent with past practice; (I) consent to any extension or waiver of
the limitations period applicable to any material Tax claim or assessment (other than in the ordinary course of business); or (J) take any action (or fail to take any action) that would result in a loss of any material Tax losses, credits or
other attributes that may be used to reduce Tax liabilities; 
 (xxii) revalue any assets or properties of the Company or its
Subsidiaries (including Inventory), except to the extent required by GAAP; or 

  
 49 













 (xxiii) agree, authorize or commit, in writing or otherwise, to take any of
the foregoing actions. 
 (c) The Supporting Lenders shall not knowingly take or permit any of their Subsidiaries to take any action that is
reasonably likely to prevent or materially impede the consummation of the Transactions. 
 Section 7.2 Access and Information.
Subject to applicable Law, the Company shall (and shall cause its Subsidiaries to) afford the Supporting Lenders and the Supporting Lenders’ officers, directors, employees, agents, counsel, accountants, investment bankers, financing sources and
other authorized Representatives reasonable access, during normal business hours and upon reasonable advance notice, to all of the Company’s, its Subsidiaries’ and their applicable Affiliates’ properties, offices and Books and Records
and, during such period, the Company shall (and shall cause its Subsidiaries to) furnish as promptly as practicable to the Supporting Lenders all information (financial or otherwise) the Supporting Lenders may reasonably request concerning its
Business; provided that no investigation pursuant to this Section 7.2 shall affect or be deemed to modify any representation or warranty made by the Company herein. Notwithstanding the foregoing, the Company shall
not be required by this Section 7.2 to provide the Supporting Lenders or their Representatives with access to or to disclose information (i) the disclosure of which would violate applicable Law, (ii) that in the
reasonable judgment of the Company would result in the disclosure of any Trade Secrets of third parties or violate any of its obligations with respect to confidentiality or (iii) to disclose any privileged information of the Company or any of
its Subsidiaries. 
 Section 7.3 Approvals and Consents; Cooperation; Notification. 

(a) Subject to the terms and conditions of this Agreement, the Company and the Supporting Lenders shall reasonably cooperate with each other
and use (and shall cause their respective Subsidiaries and Affiliates to use) their respective reasonable best efforts to take or cause to be taken all actions, and to do or cause to be done all things, reasonably necessary, proper or advisable on
their part under this Agreement and applicable Law to consummate the Transactions as soon as practicable after the date of this Agreement, including (i) unless otherwise agreed in writing by the Parties, obtaining as promptly as practicable all
necessary waiting period expirations or terminations, consents, clearances, waivers, licenses, Orders, registrations, approvals, permits, and authorizations necessary or advisable to be obtained from any third party and/or any Governmental Entity,
and (ii) preparing, filing and providing as promptly as practicable all documentation to effect all necessary notices, reports and other filings as may be necessary to obtain all such waiting period expirations or terminations, consents,
clearances, waivers, licenses, Orders, registrations, permits, approvals, permits or authorizations. Subject to applicable Laws relating to the exchange of information, the Supporting Lenders and the Company shall have the right to review in
advance, and, to the extent practicable, each will consult with the other on and consider in good faith the views of the other in connection with, all of the information relating to the Supporting Lenders or the Company or the Business, as the case
may be, and any of their respective Affiliates, that appears in any filing made with, or written materials submitted to, any third party and/or any Governmental Entity in connection with the Transactions. In exercising the rights specified in the
foregoing sentence, the Company and the Supporting Lenders shall act reasonably and as promptly as practicable. 

  
 50 













 (b) Each of the Parties shall, in connection with and without limiting the obligations set
forth in Section 7.3(a), (i) cooperate in all respects and consult with the other Parties in connection with any filing or submission with any Governmental Entity in connection with this
Section 7.3(b), including by allowing the other Parties to have a reasonable opportunity to review in advance and comment on drafts of filings or submissions and reasonably considering in good faith comments of the other
Parties and providing the other Parties with copies of filings and submissions, (ii) submit to customary background checks in connection therewith, (iii) respond promptly to any additional requests from Governmental Entities and
(iv) subject to applicable Laws and as required by any Governmental Entity, keep the other Parties reasonably apprised of the status of any waiting period expirations or terminations, consents, clearances, waivers, licenses, Orders,
registrations, approvals, permits, and authorization for the Transactions under any Antitrust Law to the extent relating to the completion of the Transactions and to the extent such party is aware of such information, including promptly furnishing
the other with copies of notices or other communications received by the Company or the Supporting Lenders or any of their respective Affiliates, as the case may be, from any Governmental Entity with respect to the foregoing clauses (i)-(iii);
provided, however, that materials required to be provided pursuant to the foregoing clauses (i)-(iv) may be redacted (A) to remove references concerning the valuation of any of the Parties or any of their respective
Subsidiaries, (B) as necessary to comply with contractual arrangements and (C) as necessary to address reasonable privilege or confidentiality concerns; provided further that any of the Parties may, as each deems
advisable and necessary, reasonably designate any competitively sensitive material provided to the other under this Section 7.3(b) as “Outside Counsel Only Material” and materials so designated shall only be
provided to each party’s outside counsel. 
 (c) Subject to applicable Laws and as required by any Governmental Entity, the Company and
the Supporting Lenders each shall keep the other reasonably apprised of the status of matters relating to completion of the Transactions to the extent such Party is aware of such information. 

(d) Notwithstanding the foregoing, nothing in this Agreement shall require the Supporting Lenders or their Affiliates to take or agree to take
any action with respect to its business or operations unless the effectiveness of such agreement or action is conditioned upon the completion of the Transactions. 

Section 7.4 Employee Communications. During the Effective Period, prior to making any broad-based written or oral
communications to officers and employees of the Company or any of its Subsidiaries pertaining to compensation or benefit matters that are affected by the Transactions, the Company shall provide the Supporting Lenders with a copy of the intended
communication, the Supporting Lenders shall have no less than three (3) Business Days to review and comment on the communication, and the Company shall consider any such comments in good faith. 

Section 7.5 Alternative Transaction Procedures. 

(a) Notwithstanding any provisions to the contrary herein, the Debtors may receive (but not actively pursue) unsolicited proposals, offers,
indications of interest or inquiries for one or more Alternative Transactions from other parties (such Alternative Transaction, a 

  
 51 













 
“Proposed Alternative Transaction”); provided that the Debtors shall promptly notify the Prepetition Agents of any Proposed Alternative Transaction within two
(2) Business Days of receipt thereof with such notice to include the material terms thereof and any accompanying documentation and/or correspondence relating to the Proposed Alternative Transaction, including (unless prohibited by a separate
agreement) the identity of the person or group of persons submitting such Proposed Alternative Transaction. 
 (b) To the extent that the
Debtors, in consultation with the Prepetition Agents, determine, in good faith and consistent with the Debtors’ fiduciary duties, that a Proposed Alternative Transaction would reasonably be expected to provide better recovery to holders of
Claims and Equity Interests in the Debtors as compared to the recovery such holders would receive pursuant to the transactions contemplated herein, including consummation of the Restructuring (such Proposed Alternative Transaction, a
“Superior Alternative Transaction”), the Debtors may negotiate, provide due diligence in connection with, discuss, and/or analyze such Superior Alternative Transaction without breaching or terminating this Agreement; provided
that a determination by the Board, in good faith, after consulting its outside legal counsel, that proceeding with the Restructuring and pursuit of confirmation and consummation of the Plan or consummation of the Transactions instead of a Superior
Alternative Transaction would be a breach of the Board’s fiduciary duties under applicable law shall be required prior to the Debtors electing to enter into a Superior Alternative Transaction; provided further that the Debtors
shall, prior to electing to enter into a Superior Alternative Transaction, provide the Prepetition Agents with seven (7) Business Days’ written notice of their intent to enter into such Superior Alternative Transaction, with such notice to
include the definitive documentation with respect to such Superior Alternative Transaction (such seven (7) Business Day notice period, the “Alternative Transaction Notice Period”). 

(c) At any time during the Alternative Transaction Notice Period, the Supporting Lenders may submit to the Debtors a proposal for one or more
Alternative Transactions (any such proposal, a “Revised Supporting Lender Proposal”). The Debtors shall, (i) promptly following the receipt of any Revised Supporting Lender Proposal, determine in consultation with the
Prepetition Agents whether the Revised Supporting Lender Proposal would reasonably be expected to provide equal or better recovery to holders of Claims and Equity Interests in the Debtors as compared to the recovery such holders would receive
pursuant to the Superior Alternative Transaction, and (ii) if so, immediately terminate any negotiations, provision of due diligence or other discussions in connection with such Superior Alternative Transaction. 

(d) If the Debtors notify counsel to the Prepetition Agents that the Debtors have entered, or will be entering, into definitive documentation
with respect to a Superior Alternative Transaction, all obligations of the Supporting Lenders shall immediately terminate and all of the Supporting Lenders’ rights shall be reserved. 

Section 7.6 Insurance. The Company shall (and shall cause its Subsidiaries to) provide the Supporting Lenders with all
cooperation, information and assistance reasonably requested by the Supporting Lenders in connection with obtaining the Post-Restructuring Insurance, including providing any prospective insurer (and its advisors and representatives) access to
information, documents and personnel as may reasonably be requested by such Persons. 

  
 52 













 ARTICLE VIII 

CONDITIONS PRECEDENT 

Section 8.1 Conditions to Obligation of the Company and the Supporting Lenders. The respective obligations of each Party to
consummate the Transactions shall be subject to the satisfaction at or prior to the Effective Date of the following conditions: 
 (a) No
Injunctions. There shall not be in effect any Order by a Governmental Entity of competent jurisdiction restraining, enjoining or having the effect of making the Transactions or the transactions contemplated by the Definitive Documents
illegal or otherwise prohibiting the consummation of the Transactions or the transactions contemplated by the Definitive Documents. No applicable Law shall have been enacted, entered, promulgated and remain in effect that prohibits or makes illegal
the consummation of the Transactions or the transactions contemplated by the Definitive Documents. 
 (b) Bankruptcy Court Orders. The
Bankruptcy Court shall not have entered an Order (i) dismissing the Chapter 11 Cases or converting the Chapter 11 Cases to a case under chapter 7 of the Bankruptcy Code, (ii) pursuant to Section 1104 of the Bankruptcy Code
appointing a trustee, receiver or an examiner to operate, manage or examine any of the Company’s businesses or (iii) that is inconsistent with this Agreement, the Plan or the Confirmation Order in a manner adverse to the Supporting
Lenders. 
 (c) No Alternative Transaction. The Company shall not have entered into definitive documentation with respect to any
Alternative Transaction. 
 Section 8.2 Conditions to Obligation of the Company. The obligations of the Company to consummate
the Transactions shall be subject to the satisfaction or waiver (to the extent permitted by applicable Law) by the Company at or prior to the Effective Date of the following conditions: 

(a) Representations and Warranties. (i) The Lender Specified Representations, determined without regard to any qualification as to
materiality, shall be true and correct in all material respects at and as of the date of this Agreement and at and as of the Effective Date as though made at and as of the Effective Date, (ii) the representations and warranties of the
Supporting Lenders contained in Article VI (other than the Lender Specified Representations) shall be true and correct, determined without regard to any qualification as to materiality, at and as of the date of this
Agreement and at and as of the Effective Date as though made at and as of the Effective Date, except for such failures to be true and correct as would not, individually or in the aggregate, reasonably be expected to (x) prevent or materially
hinder or delay any of the Transactions or the transactions contemplated by any of the Definitive Documents or (y) affect the ability of the Supporting Lenders to perform their obligations under this Agreement or the Restructuring Term Sheet or
the Supporting Lenders or any of their Affiliates to perform their respective obligations under any of the Definitive Documents, in each case, in any material respect; provided, however, that in each of the foregoing clauses (i)
and (ii), any representations and warranties that are made as of a particular date or period shall be true and correct (in the manner set forth above), only as of such date or period. 

  
 53 













 (b) Covenants and Agreements. The covenants and agreements of the Supporting Lenders
to be performed at or prior to the Effective Date shall have been performed in all material respects in accordance with this Agreement. 

(c) Confirmation Order. The Bankruptcy Court shall have entered the Confirmation Order and if a timely appeal shall have been filed or
sought, (A) no stay of the Confirmation Order shall be in effect or (B) if such a stay shall have been granted, then (1) (x) the stay shall have been dissolved or lifted and (y) the appeal would not reasonably be expected to
prevent or materially impede the consummation of the Transactions or (2) a Final Order of the district court, circuit court, or other court having jurisdiction to hear such appeal shall have affirmed the Confirmation Order. 

Section 8.3 Conditions to Obligation of the Supporting Lenders. The obligations of the Supporting Lenders to consummate the
Transactions shall be subject to the satisfaction or waiver (to the extent permitted by applicable Law) by the Supporting Lenders at or prior to the Effective Date of the following conditions: 

(a) Representations and Warranties. (i) The Company Specified Representations, determined without regard to any qualification as to
materiality, shall be true and correct in all material respects at and as of the date of this Agreement and at and as of the Effective Date as though made at and as of the Effective Date, (ii) the representations and warranties of the Company
set forth in Article V (other than the Company Specified Representations and the representations and warranties set forth in Section 5.8(f)) shall be true and correct, determined without regard to
any qualification as to materiality or “Material Adverse Effect,” at and as of the date of this Agreement and at and as of the Effective Date as though made at and as of the Effective Date, except for such failures to be true and correct
as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect and (iii) the representations and warranties of the Company set forth in Section 5.8(f) shall be true and correct
at and as of the date of this Agreement and at and as of the Effective Date as though made at and as of the Effective Date; provided, however, that, in each case of the foregoing clauses (i) through (ii), any representations and
warranties that are made as of a particular date or period shall be true and correct (in the manner set forth above), only as of such date or period. 

(b) Covenants and Agreements. The covenants and agreements of the Company to be performed at or prior to the Effective Date shall have
been performed in all material respects in accordance with this Agreement. 
 (c) Officer’s Certificates. The
Company shall have delivered to the Supporting Lenders a certificate duly executed by an executive officer of the Company certifying to the effect that the conditions set forth in Section 8.3(a) and
Section 8.3(b) have been satisfied. 
 (d) Confirmation Order. The Confirmation Order shall be a Final
Order. 
 (e) Post-Restructuring Insurance. The DIP Agent shall have received a commitment (in form and substance acceptable to the
DIP Agent in its sole discretion) from the provider(s) of the Post-Restructuring Insurance to enter into the Post-Restructuring Insurance 

  
 54 













 
with the applicable Reorganized Debtors (and their applicable Affiliates) on the Effective Date upon the effectiveness of the Plan. 

Section 8.4 Frustration of Conditions. No Party may rely on the failure of any condition set forth in
Section 8.1, Section 8.2 or Section 8.3, as the case may be, to be satisfied if such failure was caused by such Party’s breach of any provision of this Agreement.

 ARTICLE IX 

TERMINATION 

Section 9.1 Termination. 

(a) Mutual Termination. This Agreement and the obligations hereunder may be terminated by mutual written consent to terminate this
Agreement among the Company and the Supporting Lenders. 
 (b) Supporting Lender Termination. This Agreement and the obligations
hereunder shall automatically terminate one (1) Business Day (or such other notice period as specifically set forth below) following the delivery of written notice from the Supporting Lenders to the Company any time after and during the
continuance of any of the following events (each, a “Supporting Lender Termination Event”): 
 (i) a breach
of any of the covenants or agreements or any of the representations or warranties set forth in this Agreement on the part of the Company which breach, either individually or in the aggregate with other breaches by the Company, would result in, if
occurring or continuing on the Effective Date, the failure of the conditions set forth in Section 8.3(a) or Section 8.3(b), as the case may be, and such breach is not curable or, if such breach is
susceptible to cure, such breach remains uncured for a period of three (3) Business Days after receipt of notice thereof (provided that the Supporting Lenders are not then in material breach of any of the covenants, agreements,
representations or warranties set forth in this Agreement on the part of the Supporting Lenders); 
 (ii) any Debtor shall
pay or cause to be paid any amount outside of the ordinary course of business or inconsistent with the Budget (as defined in the DIP Orders), subject to Permitted Variances (as defined in the DIP Orders), without the consent of the DIP Agent; 

(iii) the Bankruptcy Court shall have entered an unstayed Order dismissing one or more of the Chapter 11 Cases or
converting any of the Chapter 11 Cases to a case or cases under chapter 7 of the Bankruptcy Code; 
 (iv) an Order
denying confirmation of the Plan shall have been entered by the Bankruptcy Court or the Confirmation Order shall have been reversed, vacated or otherwise modified in a manner inconsistent with this Agreement or the Plan without the prior written
consent of the DIP Agent; 

  
 55 













 (v) any of the Debtors move to assume any executory Contracts or unexpired
Leases without the consent of the DIP Agent inconsistent with the Plan and such assumption is not remedied within three (3) Business Days following notice thereof to the Company by the Supporting Lenders; 

(vi) any court of competent jurisdiction or governmental authority, including any regulatory authority, shall have entered a
final, non-appealable judgment or order declaring the Restructuring, this Agreement, or any material portion hereof to be unenforceable or illegal or enjoining the consummation of a material portion of the
Restructuring and such judgment or order is not stayed, dismissed, vacated or modified within five (5) Business Days following notice thereof to the Company by the Supporting Lenders; provided, however, that in the case of a
stay, upon such judgment or order becoming unstayed and five (5) Business Days’ notice thereof to the Company by the Supporting Lenders, a Supporting Lender Termination Event shall be deemed to have occurred; 

(vii) the Company fails to comply with or achieve the Milestones set forth in Exhibit D; provided,
however, the Company shall not have failed to comply with or achieve the Milestones set forth in Exhibit D to the extent that an extension of any such Milestones for up to three (3) days is required to accommodate the Bankruptcy
Court’s calendar; 
 (viii) the filing by the Company of any motion or pleading with the Bankruptcy Court that is
inconsistent with this Agreement and the Restructuring Term Sheet in any material respect and such motion is not withdrawn or appropriately modified within two (2) calendar days following notice thereof to the Company by the Supporting Lenders;

 (ix) the Bankruptcy Court grants relief that is inconsistent with this Agreement or the Restructuring and such
inconsistent relief is not dismissed, vacated or modified to be consistent with this Agreement and the Restructuring within five (5) Business Days following notice thereof to the Company by the Supporting Lenders; 

(x) any of the following shall have occurred: (a) the Company or any of its Affiliates shall have filed any motion,
application, adversary proceeding or cause of action (1) challenging the validity, enforceability, perfection or priority of, or seeking avoidance or subordination of any Claims (in any capacity) of the Prepetition Lenders or the liens securing
such Claims or (2) otherwise seeking to impose liability upon or enjoin the Prepetition Lenders (in any capacity); or (b) the Company or any affiliate of the Company shall have supported, encouraged or solicited any other party to file any
adversary proceeding or Cause of Action referred to in the immediately preceding clause (a) filed by a third party, or consents or does not object (without the consent of the DIP Agent) to the standing of any such third party to bring such
application, adversary proceeding or Cause of Action; 
 (xi) the Company (a) withdraws or revokes the Plan or files,
propounds or otherwise supports any chapter 11 plan other than the Plan or (b) files or publicly 

  
 56 













 
proposes, announces, enters into or otherwise supports any (i) Alternative Transaction or (ii) amendment or modification to the Restructuring containing any terms that are inconsistent
with the implementation of, and the terms set forth in, the Restructuring Term Sheet unless such amendment or modification is otherwise consented to in accordance with Section 10.14; 

(xii) on or after the date of this Agreement the Company consummates any merger, consolidation, material disposition, material
acquisition, material investment, dividend, incurrence of Indebtedness or other similar transaction outside the ordinary course of business that is inconsistent with the restrictions set forth in Section 7.1(b), other than
with the consent of the DIP Agent; 
 (xiii) the Definitive Documents and any amendments, modifications or supplements
thereto include terms that are inconsistent in any material respect with this Agreement or the Restructuring Term Sheet and such inconsistency has not been corrected within three (3) Business Days after notice thereof has been given by the
Supporting Lenders to the Company; 
 (xiv) the Bankruptcy Court shall have entered an unstayed Order pursuant to
Section 1104 of the Bankruptcy Code appointing a trustee, receiver or an examiner to operate and manage any of the Company’s businesses; 

(xv) the Bankruptcy Court grants relief terminating, annulling, or modifying the automatic stay (as set forth in section 362 of
the Bankruptcy Code) with regard to material assets of the Debtors without the consent of the DIP Agent; 
 (xvi) the
occurrence of any event, development, change or effect since the date of this Agreement that has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; 

(xvii) the Company ceases to have the exclusive right to file and solicit acceptances of a chapter 11 plan; or 

(xviii) the failure of the Company to pay the fees and expenses of the Supporting Lenders in accordance with
Section 10.13 of this Agreement, the Prepetition Credit Agreement, the Prepetition Facility Agreement, the Restructuring Term Sheet, and the DIP Orders and such fees and expenses are not paid within three (3) Business
Days following notice thereof to the Company by the Supporting Lenders. 
 The Company hereby acknowledges and agrees that the termination of this Agreement
and the obligations hereunder as a result of a Supporting Lender Termination Event, and the delivery of any notice by the Supporting Lenders pursuant to any of the provisions of this Section 9.1(b) shall not violate the
automatic stay imposed in connection with the Chapter 11 Cases. 
 (c) Automatic Termination. This Agreement and the obligations
hereunder shall automatically and immediately terminate if, following the delivery of any notice by the Supporting Lenders pursuant to Section 9.1(b), the Company or any other party-in-interest 

  
 57 













 
asserts that the termination of this Agreement or the delivery of such notice violates the automatic stay imposed in connection with the Chapter 11 Cases. 

(d) Company Termination. This Agreement and the obligations, hereunder may be terminated by the Company upon three (3) Business
Days advance written notice thereof to the Supporting Lenders (or such other notice period as specifically set forth below) upon the occurrence of any of the following events (each, a “Company Termination Event”) unless
(i) to the extent curable, such Company Termination Event has been cured by the applicable Supporting Lenders during such three (3) Business Day notice period (or such other applicable notice period as specifically set forth below) or
(ii) such Company Termination Event is waived in accordance with Section 10.14: 
 (i) a
breach of any of the covenants or agreements or any of the representations or warranties set forth in this Agreement on the part of the Supporting Lenders which breach, either individually or in the aggregate with other breaches by the Supporting
Lenders, would result in, if occurring or continuing on the Effective Date, the failure of the conditions set forth in Section 8.2(a) or Section 8.2(b), as the case may be, and such breach is not
curable or, if such breach is susceptible to cure, such breach remains uncured for a period of twenty (20) Business Days after receipt of notice thereof (provided that the Company is not then in material breach of any of the covenants,
agreements, representations or warranties set forth in this Agreement on the part of the Company); 
 (ii) any court of
competent jurisdiction or governmental authority, including any regulatory authority, shall have entered a Final Order declaring the Restructuring, this Agreement, or any material portion hereof to be unenforceable or illegal or enjoining the
consummation of a material portion of the Restructuring and such judgment or order is not stayed, dismissed, vacated or modified within twenty-five (25) calendar days following notice thereof to the Supporting Lenders by the Company;
provided, however, that in the case of a stay, upon such judgment or order becoming unstayed and twenty-five (25) calendar days’ notice thereof to the Supporting Lenders by the Company, a Company Termination Event shall
be deemed to have occurred; 
 (iii) the Supporting Lenders fail to provide an extension of any of the Milestones as required
to accommodate the Bankruptcy Court’s calendar; 
 (iv) Deerfield fails, at any time during the Effective Period, to
collectively hold or control 66.67% or more of the aggregate principal amount of the Prepetition Agreement Claims; or 
 (v)
the filing by the Supporting Lenders of any motion or pleading with the Bankruptcy Court that is inconsistent in any material respect with this Agreement and the Restructuring Term Sheet. 

Section 9.2 Termination Upon Effective Date or Outside Date. This Agreement shall terminate automatically without further required
action or notice upon the sooner to occur of (a) the Effective Date and (b) any Party’s written notice to the other Parties of termination 

  
 58 













 
pursuant to this Section 9.2 on or after the Outside Date; provided, however, that the right to terminate this Agreement pursuant to this
Section 9.2 shall not be available to any Party whose breach of any representation, warranty, covenant, or agreement set forth in this Agreement has been the cause of, or resulted in, the failure of the Plan to become
effective on or before the Outside Date. 
 Section 9.3 Effect of Termination. 

(a) Except as otherwise provided in this Section 9.3, in the event of termination of this Agreement in accordance
with this Article IX, (a) this Agreement shall be of no further force and effect and each Party shall be released from its commitments, undertakings and agreements under or related to this Agreement, and shall have all the rights and
remedies that it would have had it not entered into this Agreement, and shall be entitled to take all actions, whether with respect to the Restructuring or otherwise, that it would have been entitled to take had it not entered into this Agreement,
including all rights and remedies available to it under applicable law; provided, however, that the rights and obligations of the Parties under Section 10.13, if applicable, with respect to the payment of fees
and expenses incurred up to such date of termination shall survive such termination and all rights and remedies with respect to such claims shall not be prejudiced in any way; and (b) to the extent Bankruptcy Court permission shall be required
for a Supporting Lender to change or withdraw (or cause to be changed or withdrawn) its vote in favor of the Plan or any release, the Company shall support and not object to such change or withdrawal and shall use reasonable best efforts to modify
or amend its Plan or other pleadings, as applicable, to permit such Supporting Lender to change or withdraw (or cause to be changed or withdrawn) such vote or release. Nothing in this Section 9.3 shall relieve any Party
from (i) liability for such Party’s breach of such Party’s obligations hereunder or (ii) obligations under this Agreement that expressly survive termination of this Agreement pursuant to Section 10.6.

 (b) In consideration of the Supporting Lenders having expended considerable time and expense in connection with this Agreement, the Plan
and the Definitive Documentation, the Debtors shall pay to the Supporting Lenders the Expense Reimbursement Amount upon termination of this Agreement pursuant to Section 9.1 (other than pursuant to
Section 9.1(d)(i), Section 9.1(d)(iii), Section 9.1(d)(iv) or Section 9.1(d)(v)). Such Expense Reimbursement Amount shall be due and payable
within five (5) Business Days after the termination of this Agreement. The Expense Reimbursement Amount shall, subject to Bankruptcy Court approval, be treated as administrative expenses in the Chapter 11 Case under Section 503(b)(1)(A)
and Section 507(a)(2) of the Bankruptcy Code. The Debtors acknowledge and agree that: (i) the approval and payment of the Expense Reimbursement Amount are integral parts of the transactions contemplated by this Agreement; (ii) in the
absence of the Debtors’ obligation to pay the Expense Reimbursement Amount, the Supporting Lenders would not have entered into this Agreement; (iii) the entry of the Supporting Lenders into this Agreement is necessary for preservation of
the Estates and is beneficial to the Debtors because, in the Debtors’ business judgment, it will enhance the Debtors’ ability to maximize the value of their assets for the benefit of their creditors and other stakeholders; and
(iv) the Expense Reimbursement Amount is reasonable in relation to the Supporting Lenders’ costs and efforts and to the magnitude of the transactions contemplated hereby and the Supporting Lenders’ lost opportunities resulting from
the time spent pursuing the transactions contemplated hereby. 

  
 59 













 (c) Notwithstanding Section 9.3(a), the Supporting Lenders’
right to receive the one-time payment of the Expense Reimbursement Amount from the Debtors as provided in Section 9.3(b) shall be the sole and exclusive monetary remedy available to
the Supporting Lenders against the Debtors with respect to this Agreement and the transactions contemplated hereby in the event that this Agreement is terminated pursuant to Section 9.1 (other than pursuant to
Section 9.1(d)(i), Section 9.1(d)(iii), Section 9.1(d)(iv) or Section 9.1(d)(v)) (including if terminated or terminable pursuant to one or more
of such provisions), and upon such payment of the Expense Reimbursement Amount, the Debtors shall have no further liability or obligation arising out of any such breach of this Agreement or failure to consummate the Transactions in connection with
such termination event. The Parties acknowledge and agree that in no event shall the Debtors be required to pay the Expense Reimbursement Amount on more than one occasion. The Debtors’ obligations to pay the Supporting Lenders the Expense
Reimbursement Amount in accordance with the provisions of Section 9.3(b) will (i) be binding upon and enforceable against each Debtor immediately upon the Bankruptcy Court’s entering the Disclosure Statement
Order, (ii) not be terminable or dischargeable thereafter for any reason, (iii) survive any subsequent conversion, dismissal or consolidation of the Chapter 11 Case, any plan of reorganization or liquidation in the Chapter 11 Case and
(iv) survive the subsequent termination of this Agreement by any means. The Debtors’ obligations to pay the Supporting Lenders the Expense Reimbursement Amount, as and when required under this Agreement, are intended to be, and upon entry
of the Disclosure Statement Order are, binding upon (A) each Debtor, (B) any successors or assigns of any Debtor, (C) any trustee, examiner or other representative of an Estate, (D) the reorganized Debtors and (E) any other
entity vested or revested with any right, title or interest in or to a Debtor, or any other Person claiming any rights in or control (direct or indirect) over any Debtor (each of (A) through (E), a “Successor”) as if such
Successor were a Debtor hereunder. The Debtors’ obligations to pay the Supporting Lenders the Expense Reimbursement Amount, as and when required under this Agreement, may not be discharged under Sections 1141 or 727 of the Bankruptcy Code or
otherwise and may not be abandoned under Section 554 of the Bankruptcy Code or otherwise. 
 ARTICLE X 

GENERAL PROVISIONS 

Section 10.1 Agreement Effective Time. This Agreement shall become effective and binding upon each of the Parties as of the date
when counterpart signatures pages to this Agreement are executed and delivered by the Company and the Supporting Lenders. 

Section 10.2 No Solicitation. This Agreement is not and shall not be deemed to be a solicitation for votes for the acceptance of
the Plan (or any other chapter 11 plan) for the purposes of sections 1125 and 1126 of the Bankruptcy Code or otherwise or a solicitation to tender or exchange any securities. The acceptance of the Plan by the Supporting Lenders will not be
solicited until the Supporting Lenders have received the Disclosure Statement and related ballots. 
 Section 10.3 Purpose of
Agreement. Each of the Parties acknowledges and agrees that this Agreement is being executed in connection with negotiations concerning the Restructuring. 

  
 60 













 Section 10.4 Admissibility of this Agreement. Each Party agrees that this
Agreement, the Restructuring Term Sheet and all documents, agreements and negotiations relating thereto (including any prior drafts of any of the foregoing) shall not, pursuant to Rule 408 of the Federal Rules of Evidence, any applicable state
rules of evidence and any other applicable law, foreign or domestic, be admissible into evidence or constitute an admission or agreement in any proceeding involving a Party, other than the final execution versions of this Agreement and the Exhibits
thereto. 
 Section 10.5 Several, Not Joint Obligations. The agreements, representations, and obligations of the Supporting
Lenders under this Agreement are, in all respects, several and not joint. No prior history, pattern, or practice of sharing confidences among or between the Parties shall in any way affect or negate this Agreement. 

Section 10.6 Survival. Notwithstanding any termination of this Agreement pursuant to Article IX, the
agreements and obligations of the Parties in this Article X and Section 9.3 shall survive such termination and shall continue in full force and effect for the benefit of the Parties in accordance
with the terms hereof; provided, however, that any liability of a Party for failure to comply with the terms of this Agreement shall survive such termination. 

Section 10.7 Public Announcements. Unless otherwise required by applicable Law or by obligations of the Company or the Supporting
Lenders or their respective Affiliates pursuant to any listing agreement with or rules of any securities exchange or in order to enforce a party’s rights or remedies under this Agreement, the Company, on the one hand, and the Supporting
Lenders, on the other hand, shall consult with each other before issuing any other press release or otherwise making any public statement with respect to this Agreement, the Transactions or the activities and operations of the other and shall not
issue any such release or make any such statement without the prior written consent of the other (such consent not to be unreasonably withheld, conditioned or delayed). 

Section 10.8 Notices. All notices, demands, requests, consents, approvals and other communications (each, a
“Notice”) hereunder shall be in writing and delivered by (i) courier or messenger service, (ii) express or overnight mail, (iii) electronic mail, or (iv) by registered or certified mail, return receipt requested
and postage prepaid, addressed to the respective Parties as follows: 
  

	 	(a)	 if to the Supporting Lenders, to: 



Deerfield Management Company, L.P. 

780 Third Avenue, 38th Floor 

New York, New York 10017 

Email:        bsendrowski@deerfield.com 

                  epress@deerfield.com 

Attention:  Bryan Sendrowski 

                  Elliot Press 

  
 61 













 with copies (which will not constitute notice) to: 

Sullivan & Cromwell LLP 

125 Broad Street 
 New York, New
York 10004 
 Attention:    Brian E. Hamilton 

                    Ari B. Blaut 

                    James L. Bromley 

Email:         hamiltonb@sullcrom.com 

                    blauta@sullcrom.com


                    bromleyj@sullcrom.com

 and 
  

	 	(b)	 if to the Company, to: 



Endologix, Inc. 
 2 Musick 

Irvine, CA 92618 

Email:          jonopchenko@endologix.com 

Attention:    John Onopchenko, CEO 

with copies (which shall not constitute notice) to: 

DLA Piper LLP (US) 
 1251 Avenue
of the Americas 
 New York, NY 10020-1104 

Email:          thomas.califano@dlapiper.com 

Attention:    Thomas R. Califano 

or to such other addresses a Party may hereafter designate. Notice by courier or messenger service or by express or overnight mail, shall be effective upon
receipt. Notice by electronic mail shall be effective upon delivery by the sender. Notice by mail shall be complete at the time of deposit in the U.S. mail system, but any right or duty to do any act or make any response within any prescribed period
or on a date certain after the service of such Notice given by mail shall be, without further action by any Party, automatically extended three (3) days. 

Section 10.9 Descriptive Headings; Interpretative Provisions. The headings of the sections, paragraphs and subsections of this
Agreement are inserted for convenience only, and shall not affect the Agreement’s interpretation. The words “hereof,” “herein” and “hereunder” and words of like import used in this Agreement shall refer to this
Agreement as a whole and not to any particular provision of this Agreement. References to Articles, Sections, Exhibits and Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement unless otherwise specified. All Exhibits,
Annexes and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized terms used in any Exhibit, Annex or Schedule but not otherwise defined therein,
shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. Where a word or phrase is defined herein,


  
 62 













 
each of its other grammatical forms shall have a corresponding meaning. Whenever the words “include,” “includes” or “including” are used in this Agreement, they
shall be deemed to be followed by the words “without limitation,” whether or not they are in fact followed by those words or words of like import. Whenever the last day for the exercise of any right or the discharge of any duty under this
Agreement falls on other than a Business Day, the party hereto having such right or duty shall have until the next Business Day to exercise such right or discharge such duty. Unless otherwise indicated, the word “day” shall be interpreted
as a calendar day. References to “dollars” or “$” mean United States dollars, unless otherwise clearly indicated to the contrary. No summary of this Agreement prepared by or on behalf of any party hereto shall affect the meaning
or interpretation of this Agreement. 
 Section 10.10 Representation by Counsel; No Strict Construction. Each Party acknowledges
that it has been represented by counsel (or had the opportunity to be so represented and waived its right to do so) in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule of law or any legal
decision that would provide any Party with a defense to the enforcement of the terms of this Agreement against such Party based upon lack of legal counsel shall have no application and is expressly waived. This Agreement is the product of arm’s-length negotiations among the Parties and its provisions shall be interpreted in a neutral manner and one intended to effect the intent of the Parties. This Agreement shall be deemed to have been
negotiated and prepared at the joint request, direction and construction of the Parties, at arm’s length and be interpreted without favor to any Party. 

Section 10.11 Entire Agreement. Subject to the Restructuring Term Sheet and the Definitive Documents, this Agreement constitutes
the entire agreement of the Parties related to the Restructuring, and supersedes all other prior negotiations, agreements and understandings, whether written or oral, among the Parties with respect to the subject matter hereof; provided that
the Parties acknowledge that any confidentiality agreements (if any) heretofore executed between the Company and any Supporting Lender (and such Supporting Lender’s advisors) shall continue in full force and effect in accordance with and only
to the extent of their respective terms. 
 Section 10.12 Governing Law and Venue; Waiver of Jury Trial. 

(a) This Agreement, and all Causes of Action (whether in contract, tort or statute) that may be based upon, arise out of or relate to this
Agreement, or the negotiation, execution or performance of this Agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an
inducement to enter into this Agreement), shall be governed by, and enforced in accordance with, the Laws of the State of New York, including its statutes of limitations, without giving effect to any borrowing statute or applicable principles of
conflicts of law to the extent that the application of the laws (including statutes of limitation) of another jurisdiction (whether of the State of New York or any other jurisdiction) would be required thereby. 

(b) By its execution and delivery of this Agreement, subject to the commencement of the Chapter 11 Cases, each Party hereby irrevocably
and unconditionally consents to submit to the exclusive jurisdiction of the Bankruptcy Court for the purpose of any 

  
 63 













 
Cause of Action, suit or proceeding arising out of or relating to this Agreement or any of the transactions contemplated hereby. At any time prior to the filing of the Chapter 11 Cases, each
of the Parties hereby irrevocably and unconditionally submits to the exclusive jurisdiction of the state or federal courts located within in the Borough of Manhattan, the City of New York in the State of New York for purposes of any action, suit or
proceeding arising out of or relating to this Agreement or any of the transactions contemplated hereby. Each party hereto hereby consents to service of process in the manner and at the address set forth in Section 10.8.

 (c) EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY
WITH RESPECT TO ANY ACTION BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HEREBY ACKNOWLEDGES AND CERTIFIES (I) THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS
REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) IT MAKES
THIS WAIVER VOLUNTARILY AND (IV) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT, THE RESTRUCTURING TERM SHEET AND THE DEFINITIVE DOCUMENTS AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS SET FORTH IN THIS SECTION 10.12(c). 
 Section 10.13 Transaction Expenses. The Debtors
shall pay (a) one (1) Business Day prior to the Petition Date, (b) subject to the DIP Orders, including the payment procedures set forth therein, on the Effective Date and (c) otherwise in accordance with the terms of any
applicable fee letters and court orders during the pendency of the Chapter 11 Cases, all accrued and unpaid fees, costs and expenses of the Supporting Lenders in connection with the Restructuring (provided that the amount paid pursuant
to (a) above shall be agreed by the Debtors and the Supporting Lenders and shall be less than the total amount of accrued and unpaid expenses owing to the Supporting Lenders as of such date) without the need to file any application with, or
obtain any order from, the Bankruptcy Court, including, without limitation, the fees, costs and expenses of (i) Sullivan & Cromwell LLP, (ii) Houlihan Lokey Capital, Inc., (iii) local Texas counsel, (iv) any other
professionals that may be retained by the Supporting Lenders in connection with the Restructuring and (v) counsel for the Prepetition Agents. The Debtors shall also enter into ordinary and customary fee letters with the foregoing professionals
and fund the retainers and other amounts required thereunder as a condition precedent to the effectiveness of this Agreement. 

Section 10.14 Amendments and Waivers. 

(a) Any amendment or modification of any term or provision of this Agreement or the Restructuring and any waiver of any term or provision of
this Agreement or of the Restructuring or of any default, misrepresentation, or breach of warranty or covenant hereunder shall not be valid unless the same shall be in writing and (i) signed by the Company and the DIP Agent or
(ii) confirmed by email by both counsel to the Company and counsel to the 

  
 64 













 
DIP Agent representing that it is acting with the authority of the Company and the DIP Agent, respectively. 

(b) Any waiver shall not be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder
or affect in any way any rights arising by virtue of any prior or subsequent default, misrepresentation, or breach of warranty or covenant. 

(c) The failure of any Party to exercise any right, power or remedy provided under this Agreement or otherwise available in respect hereof at
law or in equity, or to insist upon compliance by any other Party with its obligations hereunder shall not constitute a waiver by such Party of its right to exercise any such or other right, power or remedy or to demand such compliance. 

(d) Notwithstanding anything to the contrary in this Section 10.14, no amendment, modification or waiver of any term
or provision of this Agreement or the Restructuring shall be effective with respect to any Supporting Lender without such Supporting Lender’s prior written consent to the extent such amendment, modification or waiver materially affects such
Supporting Lender in a manner that is disproportionately adverse to such Supporting Lender in relation to the other Supporting Lenders. 

(e) All rights, powers, and remedies provided under this Agreement or otherwise available in respect hereof at law or in equity shall be
cumulative and not alternative, and the exercise of any right, power, or remedy thereof by any Party shall not preclude the simultaneous or later exercise of any other such right, power, or remedy by such Party. 

Section 10.15 Parties, Succession and Assignment. This Agreement is intended to bind and inure to the benefit of the
Parties and their respective successors, assigns, heirs, executors, estates (including the Estates), administrators and representatives. No rights or obligations of any Party under this Agreement may be assigned or transferred to any other person or
entity except as otherwise expressly provided herein. Nothing in this Agreement, express or implied, shall give to any person or entity, other than the Parties (and those permitted assigns under Section 3.3), any benefit or
any legal or equitable right, remedy or claim under this Agreement; provided, however, that a Supporting Lender may assign some or all of its rights or delegate some or all of its obligations hereunder to one or more Affiliates without
any other Party’s consent. Upon any such permitted assignment, the references in this Agreement to the applicable Party will also apply to any such assignee unless the context otherwise requires. 

Section 10.16 No Waiver of Participation and Reservation of Right. Except as expressly provided in this Agreement or the Plan,
nothing herein is intended to, nor does, in any manner waive, limit, impair, or restrict any right of any Party or the ability of each of the Parties to protect and preserve its rights, remedies and interests, including Claims against and interests
in the Company. If the Restructuring is not consummated, or following the occurrence of a Supporting Lender Termination Event, a Company Termination Event, an event triggering automatic termination pursuant to
Section 9.1(c), or the termination of this Agreement, nothing herein shall be construed as a waiver by any Party of any or all of such Party’s rights, and the Parties expressly reserve any and all of their respective
rights. This Agreement, the Plan, and any 

  
 65 













 
related document shall in no event be construed as or be deemed to be evidence of an admission or concession on the part of any Party of any claim or fault or liability or damages whatsoever. The
Parties acknowledge that this Agreement, the Plan, and all negotiations related hereto are part of a proposed settlement of matters that may otherwise be the subject of litigation. 

Section 10.17 No Third-Party Beneficiaries. Unless expressly stated herein, this Agreement shall be solely for the benefit of the
Parties and no other person or entity shall be a third-party beneficiary. 
 Section 10.18 Counterparts; Effectiveness. This
Agreement and any amendments, joinders, consents or supplements, may be executed in one or more counterparts, each of which shall be deemed an original and all of which shall constitute one and the same agreement. Scanned signatures on this
Agreement shall be treated as originals for all purposes. Executed copies of this Agreement may be delivered by facsimile or by electronic mail in portable document format (.pdf), which shall be deemed to be an original for the purposes of this
Section 10.18. 
 Section 10.19 Severability. The invalidity or unenforceability at any time of any
provision hereof shall not affect or diminish in any way the continuing validity and enforceability of the remaining provisions hereof. If any provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other
authority of competent jurisdiction to be invalid, void or unenforceable, or the application of such provision, covenant or restriction to any Person or any circumstance, is held by a court of competent jurisdiction or other authority to be invalid,
void or unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the
remainder of this Agreement and the application of such provision, covenant or restriction to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the
validity or enforceability of such provision, or the application of such provision, in any other jurisdiction and the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in
no way be affected, impaired or invalidated. 
 Section 10.20 Specific Performance. Each Party hereto recognizes and
acknowledges that a breach by it of any covenants or agreements contained in this Agreement would cause the other Parties to sustain damages for which such Parties would not have an adequate remedy at law for money damages, and therefore each Party
hereto agrees that in the sole event of any breach, the other Parties shall be entitled to the remedy of specific performance and injunctive or other equitable relief (including attorney’s fees and costs) to enforce such covenants and
agreements, in addition to any other remedy to which such non-breaching Party may be entitled, at law or in equity, without the necessity of proving the inadequacy of money damages as a remedy, including an
order of the Bankruptcy Court requiring any Party to comply promptly with any of its obligations hereunder. 
 Section 10.21
Conflicts. In the event the terms and conditions set forth in the Restructuring Term Sheet and in this Agreement are inconsistent, the Restructuring Term Sheet shall control. In the event of any conflict among the terms and provisions of the
Plan, this 

  
 66 













 
Agreement and the Restructuring Term Sheet, the terms and provisions of the Plan shall control. In the event of any conflict among the terms and provisions of the Confirmation Order, the Plan,
this Agreement and the Restructuring Term Sheet, the terms of the Confirmation Order shall control. Notwithstanding the foregoing, nothing contained in this Section 10.21 shall affect, in any way, the requirements that the
Plan and the Confirmation Order be in all material respects materially consistent with this Agreement and the Restructuring Term Sheet and the requirements set forth herein for the amendment of this Agreement. 

[Signature Page Follows] 

  
 67 













 IN WITNESS WHEREOF, the Company and the Supporting Lenders have caused this Agreement to be
executed on their behalf as of the date first written above. 
  

			
	 ENDOLOGIX, INC.

		
	By:	 	 /s/ John Onopchenko

		 	 Name: John Onopchenko

		 	 Title: Chief Executive Office















 
			
	 SUPPORTING LENDERS:

	
	 DEERFIELD PRIVATE DESIGN FUND III, L.P.

		
	By:	 	Deerfield Mgmt III, L.P., General Partner
		
	By:	 	J.E. Flynn Capital III, LLC, General Partner
		
	By:	 	 /s/ David Clark

		 	Name: David Clark
		 	Title:   Authorized Signatory
	
	 DEERFIELD PRIVATE DESIGN FUND IV, L.P.

		
	By:	 	Deerfield Mgmt IV, L.P., General Partner
		
	By:	 	J.E. Flynn Capital IV, LLC, General Partner
		
	By:	 	 /s/ David Clark

		 	Name: David Clark
		 	Title:   Authorized Signatory
	
	 DEERFIELD PARTNERS, L.P.

		
	By:	 	Deerfield Mgmt, L.P., General Partner
		
	By:	 	J.E. Flynn Capital, LLC, General Partner
		
	By:	 	 /s/ David Clark

		 	Name: David Clark
		 	Title:   Authorized Signatory














 Schedule 1 

Company Subsidiaries 
  

	 	1.	 CVD/RMS Acquisition Corp., a Delaware corporation. 



 

	 	2.	 Nellix, Inc., a Delaware corporation. 



 

	 	3.	 RMS/Endologix Sideways Merger Corp., a Delaware corporation. 



 

	 	4.	 ELGX International Holdings GP, a Cayman Islands company. 



 

	 	5.	 Endologix International Holdings B.V., a Dutch corporation. 



 

	 	6.	 Endologix International B.V., a Dutch corporation. 



 

	 	7.	 Endologix New Zealand Co., a New Zealand unlimited liability company. 



 

	 	8.	 Endologix Bermuda L.P., a Bermuda partnership. 



 

	 	9.	 Endologix Italia S.r.l., an Italian corporation. 



 

	 	10.	 Endologix Singapore Private Limited, a Singaporean limited private company. 



 

	 	11.	 Endologix Poland sp. zo.o, a Polish limited company. 



 

	 	12.	 TriVascular Technologies, Inc., a Delaware corporation. 



 

	 	13.	 TriVascular, Inc., a California corporation. 



 

	 	14.	 TriVascular Sales LLC, a Texas limited liability company. 



 

	 	15.	 TriVascular Germany GmbH, a German limited liability company. 



 

	 	16.	 TriVascular Italia Sarl, an Italian limited liability company. 



 

	 	17.	 Endologix Canada, LLC, a Delaware limited liability company. 














 Exhibit A 

Restructuring Term Sheet 

[Attached] 












 Exhibit B 

Interim DIP Order 

[Attached] 












 Exhibit C 

Form of Transfer Joinder 

Form of Transfer Joinder 
 The undersigned
(“Transferee”) hereby (i) acknowledges that it has read and understands the Restructuring Support Agreement (the “Agreement”), dated as of July 5, 2020 among Endologix, Inc. (“Endologix”)
and the Supporting Lenders,1 and (ii) agrees to be bound by the terms and conditions thereof with respect to all of its owned or controlled Prepetition Credit Agreement Claims to the extent
and in the same manner as if Transferee was a Supporting Lender thereunder. Transferee hereby shall be deemed a “Supporting Lender” and a “Party” under the Agreement, and shall be deemed to make all of the representations and
warranties of a Supporting Lender set forth in the Agreement. 
  

			
	 [TRANSFEREE]

		
	By:	 	
                

		 	 Name:

		 	 Title:

	
	Aggregate amount of Prepetition Credit Agreement Claims (whether owned directly by such Transferee or for which such Transferee has investment or voting discretion or control):
	  

	
	 [ADDRESS]

	 Attention: [________]

	 Email: [________]



  

	1 	 Capitalized terms not defined herein shall have the meanings given to such terms in the Agreement.















 Exhibit D 

Milestones 
  

			
	With respect to the Chapter 11 Cases, no later than 11:59 p.m. (Central Time) on:
		
	 1.  Petition Date
	  	Plan, Disclosure Statement filed.
		
	 2.  Petition Date + 2 days
	  	Hearing to approve ‘first day’ motions.
		
	 3.  Petition Date + 3 days
	  	Solicitation Procedures filed.
		
	 4.  40 days after the Petition Date
	  	 Disclosure Statement approval hearing.

Disclosure Statement Order entered.

		
	 5.  60 days after the Petition Date
	  	DIP Final Order approved.
		
	 6.  75 days after the Petition Date
	  	 Confirmation Hearing to approve Plan.

Confirmation Order entered within three business days following conclusion of Confirmation Hearing.

		
	 7.  As promptly as possible after entry of the Confirmation Order but not
later than 90 days after the Petition Date
	  	Plan Effective Date.













 CONFIDENTIAL 
  

 
  

COMPANY DISCLOSURE LETTER 

TO 
 RESTRUCTURING
SUPPORT AGREEMENT1 
 AMONG 

ENDOLOGIX, INC. 
 AND

 THE SUPPORTING LENDERS IDENTIFIED HEREIN 

DATED AS OF JULY 5, 2020 
  

 
  

 

	1	 Capitalized terms used herein but not otherwise defined have the meanings ascribed to them in the Restructuring
Support Agreement. 














 Section 1.1 

“Knowledge” of the Debtors 
  

	1.	 John Onopchenko 


  

	2.	 Vaseem Mahboob 


  

	3.	 Cindy Pinto 


  

	4.	 Tim Brady 


  

	5.	 Simpson Kwan 


  

	6.	 James Tejedor 


  

	7.	 Reyna Fernandez 


  

	8.	 Tim Benner 


  

	9.	 Matt Thompson 


  

	10.	 Jeff Fecho 


  

	11.	 Jeff Brown 


  

	12.	 Mike Chobotov 


  

	13.	 Valerie Tansley 


  

	14.	 Elisa Webb 


  

	15.	 Joey Lopes 


  

	16.	 Steffanie Cook 


  

	17.	 Tim Chaplin 


  

	18.	 Carlos Ortega 


  

	19.	 Barbara Kelleter 


  

	20.	 Kimberly Stanley 


  

	21.	 Mark Phillips 


  

	22.	 Virgil Aguirre 


  

	23.	 John Washington 


  

	24.	 Janet McCusker 


  

	25.	 Vay Yam 


  

	26.	 Regional Sales Managers 














 Section 5.2 

Capitalization 
 Company
and its Subsidiaries Outstanding Equity Interests 
  

									
	 Name of Issuer
	  	 Authorized

Securities
	  	 Issued and

Outstanding Securities
	  	 Certificated
(Yes or No)
	  	 Loan Party/

Subsidiary Owner

	Endologix, Inc. 	  	170,000,000 Shares of Common Stock, $0.001 par value	  	19,299,228 Shares of Common Stock Issued and 19,173,845 Outstanding	  	Yes	  	N.A.
	  	5,000,000 Shares of Preferred Stock, $0.001 par value, 1,150,000 designated as Series DF-1 Preferred Stock	  	14,648.75 Shares of Series DF-1 Preferred Stock Outstanding	  	Yes	  	N.A.
					
	Nellix, Inc.	  	1,000 Shares of Common Stock, $0.001 par value	  	100 Shares of Common Stock	  	Yes	  	Endologix, Inc.
					
	CVD/RMS Acquisition Corp.	  	100 Shares of Common Stock, $0.001 par value	  	100 Shares of Common Stock	  	Yes	  	Endologix, Inc.
					
	RMS/Endologix Sideways Merger Corp.	  	100 Shares of Common Stock, $0.001 par value	  	100 Shares of Common Stock	  	Yes	  	Endologix, Inc.
					
	TriVascular Technologies, Inc.	  	1,000 Shares of Common Stock, $0.001 par value	  	100 Shares of Common Stock	  	Yes	  	Endologix, Inc.
					
	ELGX International Holdings GP	  	Unspecified Number of Partnership Interests	  	Unspecified Number of Partnership Interests	  	No	  	Endologix, Inc.
					
	Endologix Bermuda, L.P.	  	Unspecified Number of Partnership Interests	  	Unspecified Number of Partnership Interests	  	No	  	Endologix, Inc.
					
	Endologix Singapore Private Limited	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	No	  	Endologix, Inc.
					
	Endologix New Zealand Co.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	No	  	Endologix, Inc.
					
	TriVascular, Inc.	  	100 Shares of Common stock, $0.01 par value	  	100 Shares of Common Stock	  	No	  	TriVascular Technologies, Inc.














									
	 Name of Issuer
	  	 Authorized

Securities
	  	 Issued and

Outstanding Securities
	  	 Certificated
(Yes or No)
	  	 Loan Party/

Subsidiary Owner

	Endologix International Holdings B.V.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	No	  	Endologix Bermuda, L.P.
					
	Endologix Poland spolkda z ograniczona odpowiedzialnoscia	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	No	  	Endologix International Holdings B.V.
					
	Endologix International B.V.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	No	  	Endologix International Holdings B.V.
					
	Endologix Italia S.r.l	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	No	  	Endologix International Holdings B.V.
					
	TriVascular Sales LLC	  	1,000 Units of Membership Interests	  	1,000 Units of Membership Interests	  	No	  	TriVascular, Inc.
					
	Endologix Canada, LLC	  	1,000 Units of Membership Interests	  	1,000 Units of Membership Interests	  	No	  	TriVascular, Inc.
					
	TriVascular Italia Sarl	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	No	  	TriVascular, Inc.
					
	TriVascular Germany GmbH	  	Unspecified number of Company Interests	  	Unspecified number of Company Interests	  	No	  	TriVascular, Inc.

 Options and Equity Incentive/Compensation Plans: 

2015 Stock Incentive Plan: The Company’s 2015 Stock Incentive Plan as amended (the “2015 Plan”) authorizes the grant of
equity awards to purchase up to 5.13 million shares of Common Stock. As of June 30, 2020 approximately 1.9 million shares were reserved for issuance under outstanding stock options, including stock options granted under equity
compensation plans preceding the 2015 Plan, and approximately 730,000 shares were subject to unvested restricted stock awards. The outstanding stock options have exercise prices ranging from $4.71 to $175.80 and a weighted average exercise price of
$10.15. There have been no material changes to the items discussed in this paragraph as of the date of the Agreement. 
 Amended and
Restated 2006 Employee Stock Purchase Plan (the “ESPP”): As of June 30, 2020, approximately 374,000 shares of Common Stock were available for issuance under the ESPP. There have been no material changes to such amount as of the
date of the Agreement. 
 2017 Inducement Stock Incentive Plan: The Board has reserved 900,000 shares of the Company’s Common
Stock for issuance pursuant to awards granted under the 2017 Inducement Stock Incentive Plan. As of June 30, 2020, approximately 218,000 shares of Common Stock were available for 












 
issuance under this plan. There have been no material changes to such amount as of the date of the Agreement. 

Non-Plan Inducement Grants: In connection with its merger with TriVascular Technologies, Inc.,
on February 4, 2016 the Company issued non-plan inducement stock options to purchase 140,000 shares of Common Stock at an exercise price of $75.30 per share, and
non-plan inducement restricted stock units for approximately 8,000 shares of Common Stock. As of June 30, 2020, there were non-plan inducement stock options
outstanding to purchase approximately 14,000 shares of Common Stock of the Company at a weighted-average exercise price of $20.40 per share and zero outstanding non-plan inducement restricted stock units. 

Warrants: 
 In connection with its
merger with TriVascular Technologies, Inc. on February 3, 2016, the Company assumed unexercised out-of-the-money warrants of
TriVascular Technologies, Inc., which converted into warrants to purchase 3,508 shares of Common Stock, 2,426 at an exercise price of $125.80 per share and 1,082 at an exercise price of $282.10 per share. 

The Company has previously issued warrants to Lenders (as defined in the Prepetition Facility Agreement) to purchase an aggregate of 1,522,002
shares of Common Stock of the Company at an exercise price of $6.61 per share. 
 On April 3, 2019, the Company issued and sold a pre-paid warrant exercisable for the Company’s common stock at an exercise price of $6.61 per share to an investor, as contemplated pursuant to Equity Financing Documents (as defined in the Prepetition Facility
Agreement). The exercise price for the pre-paid warrant was fully paid at issuance and is exercisable at any time until April 3, 2029, subject to satisfaction of certain equity ownership limitations as
described in such warrant. 
 Convertible Notes: 

2020 3.25% Convertible Notes; 2024 5.0% Convertible Senior Notes: On November 2, 2015, the Company issued $125.0 million
aggregate principal amount of 3.25% Convertible Notes. Pursuant to the terms of the Prepetition Facility Agreement with Deerfield, $40.5 million of the aggregate principal amount of the 3.25% Convertible Notes was cancelled; $84.5 million
aggregate principal amount of 3.25% Convertible Notes were thereafter outstanding. At the Second Amendment Effective Date (as defined in the Prepetition Facility Agreement), approximately $73.4 million of the remaining $84.5 million of
3.25% Convertible Notes was exchanged for (i) approximately $42 million of new 5.0% Voluntary Convertible Senior Notes due 2024; and $25 million of new 5.0% Mandatory Convertible Senior Notes due 2024. At the Fourth Amendment
Effective Date (as defined in the Prepetition Facility Agreement), approximately $11.00 million of aggregate principal plus outstanding interest of the remaining outstanding 3.25% Convertible Notes will be exchanged for approximately
$11.1 million of new 5.0% Voluntary Convertible Senior Notes due 2024. 
 Pursuant to the Prepetition Facility Agreement, the Company
may issue Conversion Shares (as defined in the Prepetition Facility Agreement) pursuant to and in accordance with the terms of the Notes (as defined in the Prepetition Facility Agreement). 

Other Rights to Securities of the Company: 












 In connection with its merger with Nellix, Inc. (“Nellix”), the Company agreed to
issue shares of Common Stock to the former stockholders of Nellix upon the Company’s receipt of FDA approval to sell its Nellix EVAS System in the United States (the “PMA Milestone”). The number of shares of Common Stock issuable to
the former stockholders of Nellix upon achievement of the PMA Milestone shall equal the quotient obtained by dividing $15.0 million by the average per share closing price of Common Stock on The Nasdaq Global Select Market for each of the 30
consecutive trading days ending with the fifth trading day immediately preceding the date of the Company’s receipt of FDA approval to sell its Nellix EVAS System in the United States, subject to a stock price floor of $45.00 per
share, but not subject to a stock price ceiling. 
 Registration Rights 

Amended and Restated Registration Rights Agreement dated as of August 9, 2018, as amended, by and among the Company, the Lenders and
Agent. 
 Agreement and Plan of Merger and Reorganization, dated October 27, 2010, by and among the Company, Nepal Acquisition
Corporation, Nellix, Inc., certain of Nellix, Inc.’s stockholders listed therein and Essex Woodlands Health Ventures, Inc., as representative of Nellix, Inc.’s stockholders (Section 6.12 contains registration obligation) 












 Section 5.10 

Litigation 
 (a) 

Active Matters: Set forth below are certain legal matters that are either in active litigation or could proceed to active litigation. It
is possible that the Company’s aggregate liability arising for monetary judgements or relief arising out of these matters, and other litigation involving the Company, could be material to the Company or its Subsidiaries, however the Company
does not believe that any one of the matters discussed below (including the AFX product liability suits considered as a consolidated group) would individually result in monetary judgements or relief which would be material to the Company or its
Subsidiaries. 
  

	 	•	 	 Derivative Lawsuits: As of June 11, 2017, four shareholders have filed derivative lawsuits on
behalf of the Company, the nominal plaintiff, based on allegations substantially similar to those alleged by lead plaintiff in Vicky Nguyen v. Endologix, Inc., et al., Case No.
2:17-cv-00017 (United States District Court, Central District of California). Those actions consist of: Sindlinger v. McDermott et al., Case No. BC662280 (Los
Angeles Superior Court); Abraham v. McDermott et al., Case No. 30-2018-00968971-CU-BT-CSC
(Orange County Superior Court); and Green v. McDermott et al., Case No. 8:17-cv-01155-AB (PLAx), consolidated with Cocco v.
McDermott et al., Case No. 8:17-cv-01183-AB (PLAx) (U.S. District Court for the Central District of California). Plaintiffs
in the Sindlinger, Abraham and Green derivative actions have agreed to stay litigation pending resolution of the Nguyen action by the United States Court of Appeals for the Ninth Circuit. A related case, Ahmed v. Endologix, Inc., et al. (Filed
January 11, 2017 in the United States District Court, Central District of California; Case No. 8:17-cv-00061) was consolidated into Nguyen v. Endologix, Inc.



  

	 	•	 	 Kerr: On July 30, 2019, an action was brought in United States District Court for the Central
District of California (Case No. 8:19-cv-01457) against the Company and certain other Loan Parties by Andrew Kerr, M.D., alleging infringement of U.S. Patent Nos.
8,257,423, 9,050,182 and 10,105,209, which allegedly were issued to and are owned by Dr. Kerr. As alleged in the complaint, the accused infringing devices include the Ovation Abdominal Stent Graft System, the Ovation Prime Abdominal Stent
Graft System, the Ovation Prime, the Ovation IX Abdominal Stent Graft System, and the Ovation iX (collectively, the “Ovation Devices”). The Company believes plaintiff’s claims are without merit and is vigorously
defending the action. 


  

	 	•	 	 AFX: The Company has been named as a defendant in a number of complaints, in each case
alleging a variety of product liability-based claims pertaining to the Company’s AFX with Strata product. The Company believes it has insurance responsive to these claims, which insurance provides for a $150,000 per claim deductible and an
aggregate one million dollar aggregate deductible (for the policy year applicable to these claims). The Company believes plaintiffs’ claims are without merit and is vigorously defending the action. 



 

	 	•	 	 Kaiser: The Company has received a letter, dated January 10, 2020, from outside counsel to KP
Select, LLC, one of the Kaiser Permanent family of companies (“Kaiser”), demanding that the Company provide reimbursement to Kaiser in the amount of $4.1 million dollars for costs allegedly incurred by Kaiser for
treating patients whose AFX Endovascular AAA Systems were subject to the July 2018 recall notice. This demand was subsequently lowered to $2.8 million dollars in March 2020 The Company vigorously disputes this payment demand. Since it is
presently not possible to determine the outcome of any future discussions with Kaiser regarding this matter, and 















	 	 
whether litigation will ensue, or the outcomes associated with potential litigation, no provision has been made in the Company’s financial statements for the ultimate resolution.



  

	 	•	 	 Royalty Demand: The Company has received a letter, dated February 13, 2020, from a licensor
under one of the Company’s inbound patent license agreements alleging that the Company is in breach of certain royalty payment obligations under such agreement. In this letter, licensor has expressed a desire to reach a reasonable and amicable
resolution of this matter. The Company vigorously disagrees with this payment demand. Since it is presently not possible to determine the outcome of any future discussions with the licensor regarding this matter, and whether litigation will ensue,
or the outcomes associated with potential litigation, no provision has been made in the Company’s financial statements at this time for the ultimate resolution. Should a bona fide dispute ensure, it is possible that the Company will be required
to deposit the disputed amount into escrow pending resolution of the dispute. 


  

	 	•	 	 Other IP Infringement Notice: The Loan Parties have received notice from an individual claiming
that certain of our products read on certain issued patents held by such individual. The Loan Parties, after consultation with independent patent counsel, strongly disagrees with these claims. Since it is presently not possible to determine the
outcome of any future discussions with these individuals in regard to their patents, and whether litigation will ensue, or the outcomes associated with potential litigation, no provision has been made in the Company’s financial statements for
the ultimate resolution. 














 Section 5.11 

Intellectual Property 
 (a) 

See attached list of Registered Intellectual Property. 
 (b)

 The matters described under the headings “Kaiser” and “Other IP Infringement Notice” in
Section 5.10 are hereby incorporated by reference. 
 (d)(i) 

The matters described under the headings “Kaiser” and “Other IP Infringement Notice” in
Section 5.10 are hereby incorporated by reference. 












 Section 5.13 

Real Property 
 (b) 

Leased Real Property: 
  

					
	 Loan Party or Subsidiary
	  	 Complete street and mailing address, including zip code
	  	 Landlord name and contact

information

			
	Endologix, Inc.	  	 2 Musick, Irvine, County of Orange,
 California
92618 U.S.A.;
 33 and 35 Hammond, Irvine, County of
 Orange,
California 92618 U.S.A.
	  	The Northwestern Mutual Life Insurance Company
			
	Endologix International Holdings B.V.	  	 Europalaan 30, 5232 BC, ‘s-Hertogenbosch,

The Netherlands
	  	EL30 B.V.
			
	TriVascular Technologies, Inc.	  	3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.	  	Sonoma Airport Properties LLC
			
	Endologix Singapore Private Limited	  	6 Raffles Quay #16-01 Singapore 048580	  	JustCo (Raffles Quay) Pte. Ltd.
			
	Endologix International B.V.	  	Rahmannstraße 11, 65760 Eschborn, Germany	  	IntReal International Real Estate Kapitalverwaltungsgesellschaft mbH

 Subleased Real Property: 
  

					
	 Loan Party or Subsidiary
	  	 Complete street and mailing address, including
zip code
	  	 Landlord and sublandlord name and contact
information

	N/A	  		  	

 Other Real Property Operated or Occupied: 
  

					
	 Loan Party or Subsidiary
	  	 Complete street and mailing address, including
zip code
	  	 Nature of use

	 N/A
	  		  	













 Section 5.14(a) 

Material Contracts 
 (i) 

 

	 	1.	 Commercial Premium Finance Agreement, dated May 12, 2020 by and between the Company and First Insurance
Funding. 


  

	 	2.	 Engagement Letter, dated March 4, 2020, by and between the Company and Jefferies LLC



  

	 	3.	 Marketing & Sales Preferred Distribution Agreement, dated September 1, 2019, by and between the
Company and Merit Medical Systems, Inc. 


  

	 	4.	 Engagement Letter, dated September 7, 2017, by and between the Company and DLA Piper LLP (US).



  

	 	5.	 Master Services Agreement, dated June 24, 2020, by and between the Company and Ernst & Young LLP.



  

	 	6.	 Engagement Letter, dated September 24, 2019, by and between the Company and KPMG. 



 

	 	7.	 Engagement Letter, dated April 7, 2020, by and between the Company and FTI Consulting Inc.



  

	 	8.	 Carrier Agreement, by and between the Company and United Parcel Services, Inc. 



(ii) 
  

	 	1.	 Amended and Restated Distribution Agreement for Japan, dated July 4, 2016, by and between the Company and
Japan Lifeline (JLL), as amended by that certain Amendment No. 1 to Amended and Restated Distribution Agreement for Japan dated November 9, 2018. 


  

	 	2.	 International Distribution Agreement, dated December 31, 2018, by and between the Company and Angiocor
S.A, as amended by that certain Amendment No. 1 to International Distribution Agreement dated January 1, 2020. 


  

	 	3.	 Sales Pricing Agreement, dated November 26, 2019, by and between Scottsdale Healthcare Hospitals (d/b/a
HonorHealth) and the Company, as amended by that certain First Amendment to Sales Pricing Agreement, dated January 23, 2020. 


  

	 	4.	 International Distribution Agreement, dated January 1, 2019, by and between the Company and H.S. S.r.l.,
as amended by that certain Amendment No. 1 to International Distribution Agreement, dated February 3, 2020. 


  

	 	5.	 International Distribution Agreement, dated March 22, 2019, by and between the Company and Somnotec(S) Pte
Ltd. 


  

	 	6.	 Special Pricing Agreement, dated May 13, 2016, by and between the Company and Freeman Health Systems, as
amended. 















	 	7.	 Special Pricing Agreement, dated June 9, 2016, by and between the Company and Kaleida Health, as amended
by that First Amendment to Special Pricing Agreement dated October 15, 2018. 


  

	 	8.	 Agreement for AAA and TAA Endoprosthesis, dated as of January 1, 2019, by and between the Company and
Tenet Business Services Corporation, as amended by that certain Amendment to Agreement dated December 2, 2019. 


  

	 	9.	 Customer Contracts with the customers listed on Exhibit A of this Company Disclosure Letter



 (iii) 
  

	 	1.	 Promissory Note, dated May 1, 2020, from Bank of America, N.A. 



(vii) 
  

	 	1.	 Lease for office space located at Europalaan 30, 5232 BC,
‘s-Hertogenbosch, The Netherlands, dated July 17, 2019, by and between Endologix International Holdings B.V. and EL30 B.V. 



 

	 	2.	 Lease Agreement for Santa Rosa facility for the building located at 3910 Brickway Boulevard, Santa Rosa,
California, dated June 16, 2005, by and between Trivascular, Inc. and Sonoma Airport Properties LLC, as amended. 


  

	 	3.	 Lease Agreement for office space located at Rahmannstraße 11, 65760 Eschborn, Germany, dated
April 5, 2016 by and between Endologix Internation B.V. and IntReal International Real Estate Kapitalverwaltungsgesellschaft mbH. 


  

	 	4.	 Membership Agreement for the office space located at 6 Raffles Quay
#16-01 Singapore 048580 dated January 7, 2020, by and between Endologix Singapore Private Limited and JustCo (Raffles Quay) Pte. Ltd. 



 

	 	5.	 Standard Industrial/Commercial Multi-Tenant Lease - Net, for 2 Musick and 35 Hammond, located in Irvine,
California, dated June 12, 2013, by and between the Company and The Northwestern Mutual Life Insurance Company, as amended. 


  

	 	6.	 Standard Industrial/Commercial Multi-Tenant Lease - Net, for 33 Hammond, Suite 203 located in Irvine,
California, dated April 1, 2014, by and between the Company and The Northwestern Mutual Life Insurance Company. 


 (viii) 

 

	 	1.	 Agreement and Plan of Merger and Reorganization, dated October 27, 2010, by and among Endologix, Inc.,
Nepal Acquisition Corporation, Nellix, Inc., certain of Nellix, Inc.’s stockholders listed therein and Essex Woodlands Health Ventures, Inc., as representative of Nellix, Inc.’s stockholders. 



(ix) 
  

	 	1.	 Marketing & Sales Preferred Distribution Agreement, dated September 1, 2019, by and between the
Company and Merit Medical Systems, Inc. 














 (xiii) 
  

	 	1.	 See agreements in Section 5.14(a)(ii) above. 














 Section 5.16 

Employee Benefit Matters 
  

	 	•	 	 2020 Short Term Incentive Plan 



 

	 	•	 	 Amended and Restated 2015 Stock Incentive Plan, as amended 



 

	 	•	 	 Amended and Restated 2006 Employee Stock Purchase Plan, as amended 



 

	 	•	 	 2017 Inducement Stock Incentive Plan, as amended 



 

	 	•	 	 See Employment Agreements included as exhibits to the Company’s Form
10-K for the fiscal year ended December 31, 2019 


  

	 	•	 	 Medical Plans through Kaiser Foundation Health Plan and Aetna Health of California 



 

	 	•	 	 Dental Plan through Metropolitan Life Insurance 



 

	 	•	 	 Vision Plan through Metropolitan Life Insurance 



 

	 	•	 	 Life Insurance Plan through Metropolitan Life Insurance 



 

	 	•	 	 Short Term and Long Term Disability Plans through Metropolitan Life Insurance 



 

	 	•	 	 Health Savings Account 



 

	 	•	 	 Health Care Flexible Savings Account 



 

	 	•	 	 Pet Plan through National Casualty Company 



 

	 	•	 	 Online Healthcare Plan through Walkingspree USA Ltd. 



 

	 	•	 	 Cancer Plan through Wamberg Genomic Advisors, Inc. 



 

	 	•	 	 Coverage under COBRA 


  

	 	•	 	 Sick Leave Policy 


  

	 	•	 	 Vacation Policy 


  

	 	•	 	 Holiday Policy 


  

	 	•	 	 Endologix, Inc. 401(k) Plan through Great-West Trust Company, LLC 



 

	 	•	 	 Endologix, Inc. Severance Program 



 

	 	•	 	 Online Employee Rewards Program through Global Engagement Solutions, Inc. 



 

	 	•	 	 Legal Services and Advice through LegalShield 



 

	 	•	 	 Transportation Program with Metrolink 



 

	 	•	 	 Benefit Plans listed below: 














 Medical: 

2 Plans provided by Kaiser 
  

	 	•	 	 HMO - Core Plan 



	 	•	 	 HMO - Buy Up Plan 



4 Plans provided by Aetna 
  

	 	•	 	 HMO - Limited Network 



	 	•	 	 HMO - Full Network 



	 	•	 	 PPO 



	 	•	 	 HSA 



Dental: PPO Plan provided by MetLife 

Vision: 
 2 Plans provided by MetLife 

 

	 	•	 	 PPO 



	 	•	 	 Buy up PPO 



Flexible Spending Account : Provided by FlexFacts 

Dependent Care Flexible Spending Account: Provided by FlexFacts 

Life and AD&D: Employer paid provided by MetLife (2x annual earnings up to $200,000) 

Voluntary Plans by MetLife: 
  

	 	•	 	 Short Term Disability 


  


	 	•	 	 Long Term Disability 


  

	 	•	 	 Life and AD&D (additional policies and dependent policies) 



 

	 	•	 	 Critical illness Insurance 



 

	 	•	 	 Accident Insurance 



Additional Benefits: 
  

			
	Benefits Support Line	  	Provided by Marsh & Mclennan
		
	401k Program	  	Managed by Empower
		
	EE Stock Purchase Program	  	Managed by Endologix
		
	Employee Assistance Program	  	Provided by MetLife
		
	Benefits Support Line	  	Health Advocate













 Section 5.19 

FDA and Related Regulatory Matters 
 (b)

 FDA Facility Registrations and Device Listings: 

Endologix International Holdings B.V. (Netherlands), Registration Number 3013162347 

 

	 	•	 	 Specification Developer for: 



 

	 	•	 	 AFX Delivery System; Powerlink System (P040002) 



 

	 	•	 	 AFX introducer System (K120212) 



 

	 	•	 	 Dual Lumen Catheter (K991601) 



Endologix, Inc. (Santa Rosa, CA), Registration Number 3008011247 
  

	 	•	 	 Manufacturer for Ovation Stent Graft System (P120006) 



 

	 	•	 	 Manufacturer and Complaint File Establishment for Alto Abdominal Stent Graft System; Ovation Abdominal Stent
Graft System; Ovation iX Abdominal Stent Graft System; Ovation iX Iliac Stent Graft; Ovation Prime Abdominal Stent Graft System (P120006) 



ENDOLOGIX, INC. (Irvine, CA), Registration Number 3011063223 
  

	 	•	 	 Contract Manufacturer and Complaint File Establishment for: 



 

	 	•	 	 AFX Delivery System; Powerlink System (P040002) 



 

	 	•	 	 AFX Introducer System (K120212) 



 

	 	•	 	 Dual Lumen Catheter (K991601) 



FDA Clearances: 
 AFX Introducer System 

 

	 	•	 	 K110090 


  

	 	•	 	 K111747 


  

	 	•	 	 K120212 



Dual Lumen Catheter 
  

	 	•	 	 K991601 



FDA Approvals: 
 Ovation Platform (including
Alto Abdominal Stent Graft System ) 
  

	 	•	 	 P120006; Supplements S001 through S021, S023 through S026, S028 through S032, and S034 (withdrawn supplements not
included); and annual reports filed with FDA pertaining to such approval 


  

	 	•	 	 Ovation IDE G090239; sequentially, Supplements S001 through S045; and interim and final reports pertaining to
such investigational uses 


  

	 	•	 	 Alto IDE G160226; sequentially, Supplements S001 through S005; and interim and final reports pertaining to such
investigational uses 


 AFX Delivery System; Powerlink System: 

 

	 	•	 	 P040002; sequentially, Supplements S001 through S063; and annual reports filed with FDA pertaining to such
approval 


 Nellix Endovascular Aneurysm Sealing System: 













	 	•	 	 IDE G130005; Supplements S001 through S034 and S036 through S056 (withdrawn supplement not included); and interim
and final reports pertaining to such investigational uses 


 (d) 

The Company is subject to an action FDA Form 483 and its associated response process. In addition, the Company had a verbal Regulatory Meeting with FDA
regarding the 483 and the Company’s responses. Thus far, the Company has received no indication that a warning letter is imminent, however, in dealing with regulators it is difficult to predict their every move and reaction and, as such,
the Company cannot preclude that a warning letter may be issued until such time as the 483 and its responses are closed and recognized as such by FDA. 

(g) 
 None. 












 Section 7.1(b)(xix) 

Interim Operations 
 None. 












 Exhibit A 

[Attached]